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ABSTRACT 
 
Cancer is a disease characterized by an extreme molecular complexity. Omics 
approaches, collecting data in public databases for all the genome, transcripts and 
proteins, attempt to overcome this complexity and find the functional modules that 
perform the functions involved in tumour related processes. For instance, cancer 
tissues gene expression profiles are widely used to define genes signatures and test 
their clinical relevance. I used this kind information in order to characterise 
interesting genes in breast cancer models. On the other hand, cellular models datasets 
could provide data that permits to focus on specific molecular mechanisms and probe 
the effects of molecules in a specific cancer model. One of the most recent omics 
project is the FANTOM5 project, that has generated a unique resource, the first single 
molecule sequencing-based expression atlas in mammalian systems. Cap analysis of 
gene expression (CAGE) was used to measure transcription start sites (TSS) and 
promoter usage across a wide collection of human samples thereby identifying and 
measuring levels of the majority of coding and non-coding transcripts in the human 
genome.  
I used this information to characterize a mesenchymal/stromal stem cell line (MSC) 
derived from high-grade serous ovarian cancer (HG-SOC-MSCs) or derived from 
normal tissue (N-MSCs) included in the entire FANTOM5 human dataset. I 
highlighted shared functional programs between HG-SOC-MSCs and N-MSCs 
suggesting that the global differences between the two cell lines are based on 
quantitative levels of transcriptional output rather than on qualitative differences. The 
results suggested that HG-SOC-MSCs are close relatives of mesothelial cells and 
smooth muscle cells.  
Furthermore, we analysed the entire dataset using ScanAll, a newly developed 
software, to ab initio predict the presence of enriched elements in the genomic regions 
surrounding FANTOM5 promoters. I pinpointed regulatory modules, i.e. groups of 
enriched motifs co-occurring in co-expressed regions within a fixed distance. These 
modules are enriched in the co-expressed sequences in each sample respect to random 
generated sequences. Finally, I created a Compendium of putative expressed and 
directly interacting transcription factors. 
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AIM OF THE PROJECT 
 
Cancer is a disease characterized by an extreme molecular complexity. Several genes 
have already been identified as oncogenes or onco-suppressors, but not for all of them 
has been already identified the specific molecular mechanisms involved in the disease 
progression. With the use of high-throughput analysis we can now obtain information 
about the entire genome and transcriptome of a specific tumour or biological model, 
thus permitting to define the relationships between the different molecular elements 
that drive oncogenic processes. Omics approaches, collecting data in databases for all 
the genome, transcripts and proteins, attempt to overcome the complexity of the 
disease and find the functional modules that perform the functions involved in tumour 
related processes. One of the most recent omics project is the FANTOM5 project, that 
has generated a unique resource, the first single molecule sequencing-based atlas of 
promoters activity in mammalian systems. The FANTOM5 dataset is not strictly a 
cancer dataset, in fact it does not contain only cancer samples but also healthy tissues 
and primary cell lines: this feature allowed me to directly compare cell lines coming 
from the cancer microenvironment against both cancer cell lines and healthy tissues. 
 
During my project I performed different tasks, all of them converging in the final aim 
of highlight functional and regulatory mechanisms that are relevant for the insurgence 
and progression of cancer.  
 
1. Characterise mesenchymal stem cells derived from ovarian cancer respect the 
entire compendium of tissues and cell lines included in the FANTOM5 
dataset. 
2. Analyse the human promoterome dataset using newly developed software to 
find cis-regulatory modules that control the expression of the genes. 
3. Define the relevance of specific genes (HMGA1 and GTSE1) and their 
derived gene signatures in cancer processes using gene expression high-
throughput data. 
 
All the analyses have been performed starting from publically available cancer 
datasets or newly generated high-throughput data thus permitting not only to obtain 
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results relevant for cancer prognosis, but also to make new interesting general 
observations. 
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INTRODUCTION 
 
Introduction to Human Cancers 
Cancer is a disease in which normal cells progressively acquires a series of 
characteristics that enable them to become tumorigenic. These acquired features 
support tumour growth and metastasis through six biological capabilities. In 2000, 
Hanahan and Weinberg (Hanahan and Weinberg, 2000) described these six biological 
capabilities and named them as “hallmarks of cancer”. 
They include six essential steps that allow cells to proliferate, survive and 
disseminate: sustained proliferative signalling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis and activating 
invasion and metastasis.  
Cancer cells are able to elude the homeostatic control of cell cycle and start to 
proliferate: this is mostly due to an increased bioavailability of growth factor 
signalling molecules or circumventing negative feedback that in normal condition 
control cellular growth. So, cancer cells, in addition to increased proliferation, are 
unresponsive to suppression of growth factors, and moreover, unlike normal cells, are 
also able to escape programmed cell death. Apoptosis is usually triggered in response 
of endogenous stresses (such as DNA damage) in the intrinsic program, or by 
extracellular death-inducing signal (extrinsic program). Cancer cells adopt a variety of 
strategies to limit the apoptosis triggering; the most common way is the loss of 
damage sensor TP53, but also by increasing expression of anti-apoptotic regulators, 
and by down-regulating pro-apoptotic factors. In addition, normal cells entry in a non-
proliferative state called senescence after a limited number of cellular divisions and 
this process is controlled by the shortening of telomeres. Cancer cells have an 
increased expression of telomerase, an enzyme that adds DNA sequence repeats to the 
3' end of DNA strands in the telomere regions, thus acquiring replicative immortality. 
Like normal cells, tumours cell require nutrients and oxygen, they supply these needs 
by inducing the formation of new vessels. In the advanced stages of the disease, 
tumour cells start to invade first the surrounding tissue and then distant site forming 
metastasis. The invasion and metastasis is a multistep process, often termed the 
invasion-metastasis cascade (Valastyan and Weinberg, 2011). The process starts with 
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local invasion trough extracellular matrix and stromal cell layer, followed by 
penetration of cancer cells into blood and lymphatic vessels. The metastatic cells are 
able to extra-vasate from the lumina of such vessels into the parenchyma of distant 
tissues, surviving in a foreign microenvironment in order to form metastases 
(Valastyan and Weinberg, 2011). 
To be able to support cell growth and proliferation, cancer cells reprogram their 
cellular energy metabolism, and cells become more dependent to glucose metabolism, 
and react by upregulating glucose transport. 
A relevant factor for tumour growth and metastasis is the crosstalk between cancer 
cells and the surrounding microenvironment. Also the the immune system plays a role 
in this crosstalk by supplying bioactive molecules to the tumour microenvironment, 
such us growth factors, pro-angiogenic factors and extracellular matrix-modifying 
enzymes that facilitate angiogenesis, invasion, and metastasis (Grivennikov et al., 
2010). 
Epithelial Ovarian Cancer 
Epithelial ovarian cancer (EOC) is the gynecological disease with the highest death 
incidence. Despite relatively low morbidity, EOC presents a high mortality and the 
overall 5-year survival is still less than 30%. The death rate for this disease has not 
much changed in the last 50 years. This is mainly caused by the fact that the majority 
of early stage cancers are asymptomatic and over two-thirds of patients are diagnosed 
with advanced disease (FIGO stage III and IV, see below) (Holschneider and Berek). 
In advanced in stage the tumour spreads to the upper abdomen (stage III) or beyond 
(stage IV). The 5-year survival in these cases is only 15 to 20 percent, whereas the 5-
year survival rate for stage I disease patients approaches 90 percent and for stage II 
disease patients approaches 70 percent. 
EOC is a morphologically and biologically heterogeneous disease. Despite 
heterogeneous morphologies all EOC subtypes originate from the single layer of 
epithelial cells covering the surface of the ovaries (OSE cells), which shares a 
common embryonic origin with epithelia of Mullerian duct-derived tissues, but is 
different from the granulosa-thecal cells of the ovary. The evidence that ovarian 
epithelial cancer arises in the OSE was based on histopathological examination of 
clinical lesions (Feeley and Wells, 2001). OSE cells go through repeated cycles of 
proliferation with the growth and rupture of ovarian follicles and this process is 
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regulated by the interaction between mesenchyme and epithelium (Murdoch and 
McDonnel, 2002). Deregulation of such micro-environmental regulatory interactions 
could represent the basis of ovarian cancer progression, whereby molecular pathways, 
defined by growth factors and hormones, have been suggested to be critically 
involved. This is supported by the fact that the normal OSE cells retain a high degree 
of plasticity, being able to acquire mesenchymal or epithelial phenotypes (Auersperg 
et al., 2001).  
From the histopathological point of view EOC are among the most complex of all 
human malignancies. One of the most particular aspects of ovarian carcinogenesis is 
the change in differentiation that accompanies neoplastic progression. OSE is a 
simple, rather primitive epithelium with some stromal features, but as it progresses to 
malignancy it loses its stromal characteristics and acquires the characteristics of the 
Mullerian duct-derived epithelia, i.e., the oviduct, endometrium, and uterine cervix. 
This aberrant differentiation occurs in such a high proportion of ovarian carcinomas 
that it serves as the basis for the classification of these cancers as serous (fallopian 
tube-like), endometrioid (endometrium-like), and mucinous (endocervical-like) 
adenocarcinomas. Tumours in which is impossible to establish any resemblance with 
Mullerian derived tissues are indicated as undifferentiated tumours. Serous 
adenocarcinomas comprise approximately 80% of all epithelial ovarian cancers. At 
the cellular level, Mullerian differentiation is expressed by the appearance of altered 
cell shapes, E-cadherin, junctional complexes, epithelial membrane antigens, and 
secretory products including mucins and CA125 antigen. Thus, unlike carcinomas in 
most other organs in which epithelial cells become less differentiated in the course of 
neoplastic progression than the epithelium from which they arise, the differentiation 
of ovarian carcinomas is more complex than that of OSE: EOC, in fact, forms 
polarised epithelia, papillae, cysts, and glandular structures. 
In addition to the histological classification, EOC are also given a grade and a stage 
after surgery. The grade is based on both architectural and cytological features and is 
on a scale from 1 to 3. Grade 1 EOC more closely resembles normal tissue and tends 
to have a better prognosis than Grade 3 EOC. It is noteworthy that there are several 
other rare histotypes that have been described: Brenner tumours, Mixed Epithelial 
Tumours, and the Small Cell Carcinomas. 
Genome-wide study approaches represent a suitable tool for identification of 
molecular factors involved in the EOC and in this perspective recent studies have 
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reported the characterization of gene expression profiles of this type of malignancy 
and of derivative cell lines (Welsh et al., 2001). These molecular profiling studies 
have supported the notion that different subtypes likely represent distinct disease 
entities (TCGA, 2011). 
 
Breast cancer 
Breast Cancer is the most common cancer, and the worldwide leading cause of cancer 
death among women. Despite this, death rates from breast cancer have been declining 
since about 1989. These decreases are the combined result of earlier detection through 
screening and improved treatment. Most patients die due to distant metastases that are 
frequently unresponsive to therapies. 
Breast cancer is an heterogeneous disease from a clinical, morphological and, first of 
all, molecular point of view. The development of high throughput technologies has 
allowed the classification of breast cancer based on molecular characteristic and not 
only looking phenotypic parameters (such us tumour size, lymph node involvement, 
grade, and age) (Perou et al., 2000; Sørlie et al., 2001). Gene expression profiling of 
breast cancer sample allowed identification of five major molecular subtypes: luminal 
A, luminal B, HER2 positive, basal-like and claudin-low. 
Luminal A is the most common subtype among breast cancers (50-60% of all cases). 
It is defined by immunohistochemistry as estrogen receptor (ER) positive, and HER2 
negative, characterized by low proliferation rate and usually have a good prognosis. 
Luminal B (10-20% of all BC) tumours have a high proliferation rate, estimated by 
Ki67 proliferation-related antigen staining. They have a worse prognosis than 
Luminal A but they respond to chemotherapy. Her2-positive subtype represents 10-
15% of breast cancer and highly expresses HER2 gene or genes associated with the 
HER2 pathway. Commonly they are diagnosed at a high histological grade, and are 
characterized by poor prognosis. 
10-20% of BC corresponds to basal-like subtype: they have poor prognosis, with high 
mitotic index, high metastatic relapse in visceral organs (lung, central nervous system, 
lymph nodes). Triple negative breast cancers (TNBC) are the most common sub-
group of basal breast: they are negative for ER, PGR and HER2 expression. 
Treatment for this subtype is very difficult, as well as identification of new 
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therapeutics targets. The most frequent alterations are p53 mutations and impaired 
activity of BRCA1 (Bertucci et al., 2012). 
Another subtype is the Claudin-low subtype, whose predominant feature is low 
expression of tight junctions and intracellular adhesion genes (claudin-3, - 4, -7 and 
E-cadherin) and overexpression of immuno-response related genes, due to high 
immune-system infiltration (Prat et al., 2010). This sub-group has a poor prognosis. 
Normal Breast cancer is a poorly characterized subtype of breast cancer: it occurs 
only in 5-10% of cases end it express genes typical of adipose tissue. It lacks ER, 
PGR and HER2 receptor, but it is also missing of CK5 and EGFR basal marker. 
Usually this kind of BC displays an intermediate prognosis and response to 
chemotherapy. The classification into subtypes of breast cancer based on molecular 
features could permit to stratify breast cancer patients and treatments. Nevertheless, 
processes and pathways in cancer progression and metastasis still need to be 
investigating in order to better define treatment and prognosis for the various breast 
cancer subtypes. 
Adult Stem cells and cancer 
Stem cells, as classically defined, are cells with a capacity to self-renew and to 
generate daughter cells that can differentiate down several cell lineages to form all of 
the cell types that are found in the mature tissue. A stem cell might go through an 
asymmetric cell division to generate one cell that is identical to the stem cell itself and 
one cell that is distinct and more differentiated. The identical cell provides for self- 
renewal of the stem cell compartment; the distinct cell goes through a series of cell 
divisions and differentiation steps to generate the ultimate terminally differentiated 
cell populations. The cells that form the intermediates between stem cells and 
terminally differentiated cells are usually referred to as progenitor cells (especially if 
they give rise to a defined structure or cellular compartment), transit cells or transit 
amplifying cells. Stem cells could also generate distinct daughter cells by dividing 
symmetrically into two identical cells, followed by a random decision based on, for 
example, variation in intensity of cell signalling to establish one daughter cell as a 
new stem cell and the other as a transit cell. 
Stem cells can be divided into two functional classes. First, there are stem cells that 
are responsible for tissue renewal. Such cells are found, for example, in bone marrow, 
in the skin and in the intestine, and are responsible for replacing terminally 
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differentiated cells as they mature and die or are shed from an epithelial surface. 
These cells are continually active, although at a slow rate. Second, there are stem cells 
that are inactive until required in response to environmental factors, for example, to 
repair tissue damage. Satellite cells of muscle might be an example of such a stem 
cell, as might putative liver stem cells that have been suggested to be responsible for 
liver regeneration. 
Types of Human Adult stem cells 
The best characterized types of human adult stem cells in vertebrates are: 
HSCs Hematopoietic Stem Cells  
NSCs Neural Stem Cells/oligodendrocyte progenitors  
IPSCs Induced Pluripotency Stem Cells  
MSCs Mesenchymal Stem Cells  
CSCs Cancer Stem Cells   
 
HSC Hematopoietic Stem Cells:  the stem cells that form blood and immune cells are 
known as hematopoietic stem cells. They are ultimately responsible for the constant 
renewal of blood. The first evidence and definition of blood-forming stem cells came 
from studies of people exposed to lethal doses of radiation in 1945.  In the early 
1960s, Till and McCulloch began analysing the bone marrow to find out which 
components were responsible for regenerating blood (Till and McCulloch, 2012) 
 Nowadays hematopoietic stem cell is defined as a cell isolated from the blood or 
bone marrow that can renew itself, can differentiate to a variety of specialized cells, 
can mobilize out of the bone marrow into circulating blood, and can undergo 
programmed cell death (apoptosis).  
 
NSCs Neural Stem Cells: adult NSCs, which are generated from the precursors that 
build the nervous system during development are maintained into adulthood in at least 
two niches, the sub-ventricular zone (SVZ) of the lateral ventricles and the sub-
granular zone (SGZ) in the hippocampus, although there is lively discussion 
concerning the possibility that NSCs are more widely scattered throughout the adult 
brain (Gould, 2007). 
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IPSC Induced pluripotent stem cells: in 2006, Takahashi and Yamanaka at Kyoto 
University in Japan identified conditions that would allow specialized adult cells to be 
genetically "reprogrammed" to assume a stem cell-like state. These adult cells, called 
induced pluripotent stem cells (iPSCs), were reprogrammed to an embryonic stem 
cell-like state by introducing genes important for maintaining the essential properties 
of embryonic stem cells (ESCs) (Takahashi and Yamanaka, 2006). This approach 
involves taking mature "somatic" cells from an adult and introducing the genes that 
encode critical transcription factor proteins, which themselves regulate the function of 
other genes important for early steps in embryonic development. In the initial 2006 
study, it was reported that only four transcription factors (Oct4, Sox2, Klf4, and c-
Myc) were required to reprogram mouse fibroblasts (cells found in the skin and other 
connective tissue) to an embryonic stem cell–like state by forcing them to express 
genes important for maintaining the defining properties of ESCs. These factors were 
chosen because they were known to be involved in the maintenance of pluripotency, 
which is the capability to generate all other cell types of the body. The newly-created 
iPSCs were found to be highly similar to ESCs and could be established after several 
weeks in culture (Maherali et al., 2007). 
 
MSCs Mesenchymal Stem Cells: more than 30 years ago it has been reported that 
fibroblast-like cells coming from bone marrow via attachment to tissue culture plastic 
were inherently osteogenic (Friedenstein et al., 1974). Osteogenic cells were actually 
capable of differentiating into multiple connective tissue cell types at a clonal level 
(Dennis et al., 1999), which validated the concept of a mesenchymal stem cell. 
Nowdays, MSCs are defined as adherent, fibroblastoid-like cells that are able to 
differentiate to osteoblasts, adipocytes, and chondrocytes in vitro . 
In addition to bone marrow, MSCs or MSC-like cells have also been elaborated from 
skeletal muscle, adipose tissue, umbilical cord, synovium, the circulatory system, 
dental pulp, and amniotic fluid (Williams et al., 1999)(Zuk et al., 2001)(Erices et al., 
2000)(De Bari et al., 2001)(Kuznetsov et al., 2001). 
Therefore, it appears that MSCs reside within the connective tissue of most organs. 
However, it should be noted that these populations are not functionally equivalent 
with respect to their differentiation potential. Also, clonal studies have shown that 
plastic adherent populations isolated from bone marrow are functionally 
heterogeneous and contain undifferentiated stem/progenitors and lineage-restricted 
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precursors with varying capacities to differentiate into connective tissue cell types 
(Muraglia et al., 2000). Therefore, characterizing populations as MSC or MSC-like 
also depends, in part, on the methods used to evaluate their differentiation potential. 
Finally, because MSCs also generate the stromal component of bone marrow, 
adherent populations contain cells that express adhesion molecules and cytokines that 
regulate aspects of hematopoiesis (Deryugina and Müller-Sieburg, 1993). 
Despite their functional heterogeneity, MSC populations obtained from most tissues 
commonly express a number of surface receptors including CD29, CD44, CD49a-f, 
CD51, CD73, CD105, CD106, CD166, and Stro1 and lack expression of definitive 
hematopoietic lineage markers including CD11b, CD14, and CD45. MSCs that 
express the aforementioned surface markers and are capable of differentiating into 
connective tissue cell types can be enriched from peripheral and umbilical cord blood 
by selection for CD133 and from bone marrow by selection for stage-specific 
embryonic antigen (SSEA)-1, SSEA-4, or the nerve growth factor receptor CD271. 
Other studies have shown that bone marrow-derived MSCs express the pericyte- 
specific markers CD146 and 3G5 (Shi and Gronthos, 2003) consistent with the fact 
that specialized vascular pericytes in bone marrow are thought to represent the closest 
in vivo approximation to MSCs. However, it is important to realize that no single 
isolation method is regarded as a standard in the field. Therefore, the varied 
approaches used to culture-expand and select for MSCs make it difficult to directly 
compare experimental results. Moreover, some isolation schemes introduce epigenetic 
and genetic changes in cells that may dramatically affect their plasticity and 
therapeutic utility. Finally, human MSCs exhibit some variation in their pattern of 
expressed genes among different donor preparations using the same isolation 
protocols, and larger variations as sparse cultures become confluent and are expanded 
by serial passage and approach senescence. Many hypotheses on the in situ original 
cells from which MSCs descend have been raised, but a final answer is to be given. 
 
Cancer stem cells: mutations that deregulate the pathways that control normal stem-
cell self-renewal cause a diverse range of cancers (Reya et al., 2001). This indicates 
that cancer can be considered a disease of unregulated self-renewal in which 
mutations convert normal stem-cell self- renewal pathways into engines for neoplastic 
proliferation. Indeed, stem cells are appealing candidates as the 'cell of origin' for 
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cancer because of their pre-existing capacity for self-renewal and unlimited 
replication. 
When cancer cells of many different types were assayed for their proliferative 
potential in various in vitro or in vivo assays, only a small minority of cells were able 
to proliferate extensively. This gave rise to the idea that malignant tumours are 
comprised of both cancer stem cells, which have great proliferative potential, as well 
as more differentiated cancer cells, with limited proliferative potential. So, the growth 
and progression of many cancers could be driven by a minority population of cancer 
stem cells. 
The discovery of multipotent progenitor cells with the capacity for self-renewal 
outside the hematopoietic system raises the possibility that cancer stem cells could 
arise from other tissue stem cells and initiate other cancer types, including solid 
cancers. Consistent with this possibility, uncultured specimens of human breast 
cancer cells from patients were separated into fractions that expressed different 
surface molecules, and then injected into immunodeficient mice. Again, only a small 
population of the tumour cells was able to induce tumour formation in the mice (Al-
Hajj et al., 2003). These findings indicate that, like teratocarcinoma cells and AML 
cells, breast cancer cells intrinsically differ in their tumorigenic potential. 
 
The tumour niche 
Analysis and reconstruction of the hierarchal cellular organization and homeostasis 
within tumour tissue and along its development represent the most challenging 
present goals in cancer research. The dissection and characterization of the distinct 
cellular lineages and their respective progenitors giving rise to the various cell types 
that form the tumour-tissue could be addressed through the use of defined in vitro 
growth models. 
At present we know that tumour initiation, invasion and progression are determined 
by molecular and phenotypic alterations arising not only in the tumour cells, but also 
in their microenvironment. Microenvironment supports malignant growth and the 
molecular mechanisms and stromal cells may contribute to tumorigenesis. In fact, the 
heterogeneous nature of the microenvironment confers a large degree of diversity in 
gene expression and signalling throughout the tumour, resulting in the creation of 
subpopulations of tumour cells that exhibit phenotypic diversities and differential 
sensitivity to various forms of treatment. Stromal cells within the tumour, also defined 
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as CAFs, may derive from various sources including their recruitment from an 
external Mesenchymal-Stem-Cell compartment. It has been shown that Bone Marrow 
derived Mesenchymal-Stem-cells respond to chemotactic signals originating from the 
tumour cells (Karnoub et al., 2007) and acquire the characteristics of CAFs after 
exposure to tumour-conditioned medium (Mishra et al., 2008). Within the tumour 
recruited MSC cells could be capable of self-sustaining and expanding as internal 
colonies thus maintaining their own homeostasis in response to the selection pressure 
imparted by the tumour cells whose crosstalk should define the basic mechanisms of 
the reciprocal expansion. MSCs have been shown to increase the kinetics of 
implantation and facilitate metastasis in a breast cancer xenograft model. (Karnoub et 
al., 2007). MSC derived from normal tissues have multipotent potential characterized 
by plastic adhesion properties, differentiation potential and marker expression. 
Tumour derived stromal cells differ from normal stromal cells in their committed 
maintenance of an activated state which has been shown, for breast cancer, to most 
likely depend on epigenetic modifications. This has been recently reinforced also for 
ovarian serous carcinoma, where evidence has been provided that the tumour stromal 
compartment does not present clear signs of somatic alterations (Qiu et al., 2008). 
DNA microarrays: an invaluable tool for functional genomic exploration 
The introduction of automated large-scale sequencing, supported by adequate 
computational tools and bioinformatics development, has greatly increased our 
general knowledge on genomic sequences organisation and function. Nowadays, it is 
possible to analyse thousands of genes in a single assay. Serial analysis of gene 
expression (SAGE) (Velculescu et al., 1995), oligonucleotide arrays (Lockhart et al., 
1996) and cDNA microarrays (Schena et al., 1996) are among the major techniques 
developed for this type of analysis. In microarray analysis the Northern blotting 
scheme is reversed: the labelled moiety is obtained from the RNA sample and a 
certain number of immobilised known sequences are used as probes. The 
advancements in robotics allowed miniaturising the scale of the reactions and 
modified microscope slides could be used to deposit thousands of nucleic acid 
sequences. The same result was also obtained by borrowing photolithography 
techniques from the semiconductor manufacturing to synthesize oligonucleotides 
directly onto a solid support. Altogether these progresses leaded, in 1995, to the first 
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papers in which the term “microarray” was used in its current meaning (Schena et al., 
1998). 
Principles of microarray analysis 
Microarrays are miniaturised hybridisation assays that permit to simultaneously 
querying thousands of nucleic acid fragments. All microarray systems share the 
following components: 
• The array, which contains the immobilised nucleic acid sequences, known as 
“probes”;  
• One or more labelled samples or “targets” that are hybridised against the 
microarray;  
• A detection system that quantify the hybridisation signals. 
Microarrays and DNA-chips 
Spotted microarrays consist of a collection of preformed nucleic acid sequences 
immobilised onto the solid support so that each unique sequence forms a tiny feature 
called “spot”. These nucleic acids are obtained in numerous ways, and there are 
different methods for depositing them onto microarray slides (by simple contact, by 
inkjet technology, or by micro-syringe pumping for instance). In general nucleic acid 
prepared for deposition on microarrays consist of cDNA clones amplified by 
polymerase chain reaction (cDNA microarrays), or of synthesised oligonucleotides of 
various length (oligonucleotide microarrays). The size of the spots differs from one 
system to another, but it is usually less than two hundred micrometers in diameter. A 
modified glass slide or glass wafer acts as the solid support onto which up to tens of 
thousands of spots can be arrayed in a total area of a few square centimetres. On the 
contrary, DNA-chips are produced by a proprietary technology (GeneChip, 
Affymetrix) quite different from the spotted one, as it is based on direct 
photolithography synthesis of short oligonucleotides (20-25 base pairs) on the solid 
support. 
Target labelling and microarray hybridization 
Whatever the kind of microarray used, DNA probes present on the arrays are 
interrogated by nucleic acid hybridisation with a labelled target. The sample may be 
mRNA for a gene expression study or genomic DNA for other purposes (promoter 
usage analysis: CHIP-on-Chip, genomic rearrangements: FISH-on Chip). The sample 
is converted to a labelled population of nucleic acids, known as the target. These 
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moieties consist of several thousands of different labelled nucleic acid. Therefore, 
these hybridisations should be carried out under conditions that do not promote 
annealing of non-complementary fragments. Fluorescent dyes, and especially the 
cyanine dyes Cy3 and Cy5, have been widely adopted as the predominant labels in 
microarray analysis. Fluorescence has the advantage of permitting the detection of 
two or more different signals in one experiment. This has thus allowed investigators 
to perform comparative analysis of two or more samples on one microarray.  
Then the labelled fragments in the target are expected to form duplexes with their 
immobilised complementary probes. This phase, called hybridization, requires that 
the nucleic acids are single-stranded and accessible to each other. The number of 
duplexes formed reflects the relative number of each specific fragment in the target, 
as long as the amount of immobilised nucleic acid probe is in excess and not 
restraining the kinetics of hybridisation. Two or more samples labelled with different 
fluorescent dyes can be hybridised simultaneously, resulting in simultaneous 
hybridisation taking place at each spot. By measuring the different fluorescent signals 
associated with each feature, the relative abundance of specific sequences in each of 
the samples can be determined. 
Scanning and data analysis 
Microarray scanners typically contain two different lasers that emit light at 
wavelengths that are suitable for exciting the fluorescent dyes used as labels. A 
detector system attached to a confocal microscope records the emitted light from each 
feature of the array, permitting high-resolution detection of the hybridisation signals. 
Alternative solutions use CCD-camera devices to detect the fluorescence. Despite 
their small size, microarrays allow the generation of a large amount of data even from 
a single hybridisation. For these reasons the use of computerised data processing is 
necessary in order to handle the amount of generated data and to gain maximum 
information from the experiment. This is usually achieved by specialised software 
that extracts primary data from scanned microarray slide images, normalises this data 
to remove the influence of experimental variation, and finally manipulates the data so 
that biologically meaningful conclusions can be made. 
Applications of microarray analysis 
Microarrays represent a high-power approach to perform analyses that were 
previously time consuming. Due to the availability of millions of data points at once, 
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microarrays enabled global analysis of fundamental biological processes: gene 
expression analysis, genome analysis, and drug discovery have been three of the main 
areas in which microarray analysis has been applied so far. 
Gene expression analysis 
Gene expression analysis examines the composition of cellular messenger RNA 
populations. Traditional gene expression analysis was based on techniques such as 
Northern blotting, RT-PCR and nuclease protection assays, as well as on more 
advanced methods, such as differential display, subtractive hybridisation, cDNA 
fragment fingerprinting, and serial analysis of gene expression (SAGE). These 
techniques were largely used in the past and have enabled the discovery of novel 
differentially expressed genes. However, the technical challenges of these methods 
still limit their use to the analysis of just a few samples at a time, while microarray 
analysis allows the examination of thousands of genes in multiple samples with 
relative simplicity. 
In the simplest scheme a typical microarray gene expression experiment compares the 
relative expression levels of specific transcripts in two samples. Usually one of the 
samples is a control while the other is obtained from cells whose response or status is 
being explored. Each one of the two samples is labelled with a different fluorescent 
dye, and equal amounts of the labelled samples are combined and hybridised with the 
microarray. After hybridisation two grey scale images (usually in a 16-bit TIFF 
format) corresponding to the fluorescent signals of the two dyes are independently 
obtained by scanning the microarray and fluorescence intensity from each feature is 
subsequently quantified by a specific software. After normalization, the intensity of 
the two hybridisation signals can be compared: equal signal from both samples 
suggests equal expression of the considered genes in both samples, while signals 
disparity is suggestive of differential expression. 
One of the most important remarks that have to be taken into account is that 
microarray analysis does not give any information about absolute gene expression 
levels in the samples. This is because the intensity of the fluorescent signals is not 
only proportional to the number of hybridised fragments, but also to the length of 
these fragments and the number of fluorescent labels each fragment carries (specific 
activity of the target or labelling density). These parameters are determined by the 
unique nucleotide sequence of each transcript, so that they will vary from gene to 
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gene. If the two samples have been labelled under similar conditions, the length and 
labelling density of specific transcripts will be similar, allowing the comparison of the 
relative abundance of the transcripts in the analysed targets. 
In cancer research microarrays have been intensively used to find gene expression 
changes in transformed cells and metastases, to identify diagnostic markers, and to 
classify tumours based on their gene expression profiles (Alizadeh et al., 2000). 
 
Cancer datasets 
Cancer can take hundreds of different forms depending on the tissue of origin and the 
spectrum of genomic alterations. These differences affect the oncogenesis process and 
therapeutic response. Although many genomic events with direct phenotypic impact 
have been identified, much of the complex molecular landscape remains not 
characterized.  
Large numbers of oncogenes had been identified using functional assays on genetic 
material from tumours in positive-selection systems (Alitalo et al., 1983; Shimizu et 
al., 1983; Soda et al., 2007), and a subset of tumour suppressor genes was identified 
by analysing loss of heterozygosis. 
The advent of microarray allowed collecting gene expression data coming from 
cancer samples, creating large cohorts of patients of which clinical information is also 
available. This approach permitted to draw relationships between gene expression 
patterns and clinical and prognostic features of cancer. 
More recently, systematic cancer genomics projects, have applied emerging 
technologies to the analysis of specific tumour types. This approach has identified 
novel oncogenic genes and (Davies et al., 2002; Mardis et al., 2009; Tomlins et al., 
2005), has established definitions of molecular subtypes (TCGA, 2011, 2012) and has 
identified new biomarkers. Importantly, some of these biomarkers have important 
clinical implications (Perou et al., 2000; TCGA, 2013). 
The increased number of tumour samples improves the ability to detect and analyse 
molecular aberrations in cancers. The use of large cohorts has enabled DNA 
sequencing to uncover a list of recurrent genomic aberrations, both known and novel, 
as common events across tumour types (Vogelstein et al., 2013). Indeed, a majority of 
the cancer samples have distinct alterations not shared with other samples. Despite the 
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apparent uniqueness of each individual tumour, the set of molecular aberrations often 
integrates into known biological pathways that are shared by sets of tumour samples.  
The results of molecular analysis are now revealing that cancers of different organs 
may share many features, whereas, cancers from the same organ but of different sub-
type are often quite distinct. 
Important similarities among tumour sub-types from different organs have already 
been identified. For example, TP53 mutations drive high-grade serous ovarian, serous 
endometrial and basal-like breast carcinomas, all of which share a global 
transcriptional signature involving the activation of similar oncogenic pathways 
(Ciriello et al., 2013; Kandoth et al., 2013; TCGA, 2012). 
Shared molecular patterns will enable therapeutic discoveries in one disease to be 
applied to other types of cancer.  
 
Next-generation sequencing 
With the advent of capillary electrophoresis (CE)-based Sanger sequencing, scientists 
gained the ability to elucidate genetic information from any given biological system.  
The concept behind next-generation sequencing (NGS) technology is similar to 
Sanger sequencing: the bases of a small fragment of DNA are identified from signals 
emitted as each fragment is re-synthesized from a DNA template strand. NGS extends 
this process across millions of parallel reactions. This method enables fast sequencing 
of large sequences of DNA spanning entire genomes, with the newest instruments 
capable of producing hundreds of gigabases of data in a single run.  
Several NGS platforms are commercially available (Metzker, 2010). Most of them are 
based on sequencing-by-synthesis technology. Roche 454, Illumina, Helicos, and 
PacBio (Pacific Biosciences) use a DNA polymerase to drive their sequencing 
reaction, while SOLiD (Life Technologies) and Complete Genomics use a DNA 
ligase. The sequencing platforms can be single molecule-based (sequencing a single 
molecule, such as Helicos and PacBio) or ensemble-based (sequencing of multiple 
identical copies of a DNA molecule, such as Illumina and SOLiD). 
Sample preparation and amplification phase change between different platforms, 
hence the selection of a sequencing platform depends on the experimental goals. For 
example, the sample preparation protocol for Helicos is relatively simple and might 
be preferred if the amount of RNA sample is limiting. Helicos avoids the polymerase 
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chain reaction (PCR) amplification step, giving a direct reflection of RNA expression 
levels. These characteristics are typical for all single molecule sequencing (SMS) 
platforms. Generally, non-SMS platforms use amplification steps. Amplification-
based protocols can provide relative expression levels for most RNAs but require 
more controls. 
On the other hand single-molecule-based platforms such as Helicos have a high error 
rate (5%). A higher error rate makes it more difficult to match sequencing reads with 
a reference genome and lowers the number of usable reads. If a low sequencing error 
rate is needed, Illumina or SOLiD are often the best choices (< 1). The advantage of 
low error rates is particularly important for microRNA (miRNA) sequencing. Because 
of the relatively small sizes of miRNAs (ranging from 15 to 27 nt, with most 20 to 22 
nt long on average), high error rates cause many raw reads to be lost at the alignment 
stage. Whatever platform is chosen, higher sequencing capacity renders lowly 
expressed transcripts to be detected more easily. 
 
RNA-seq 
RNA sequencing (RNA-seq) is the application of any of a variety of next-generation 
sequencing techniques to study RNA. RNA-seq library preparation usually includes 
reverse transcription. Data analysis of RNA-seq could give information and 
quantitation about alternatively spliced transcript and novel transcript. 
Transcriptome assembly is necessary to transform individual reads into sequences of 
entire mRNAs or noncoding transcripts. 
Library preparation for RNA-seq consist in converting cellular RNA into molecules 
that can be easily sequenced. Ribosomal RNAs (rRNA) are abundant in the cell and 
can comprise up to 80% of total cellular RNA. rRNA may be removed by an 
enzymatic degradation approach (such as duplex specific nuclease treatment). This 
helps ensure that rare transcripts are sequenced to adequate depth. 
Depending on the chosen sequencing platform, RNA can be fragmented, usually by 
chemical hydrolysis or enzymatic digestion to a appropriate size. In some cases the 
RNA species under investigation, such as miRNAs, are small (under 200 bases) and 
so the fragmentation phase is not required. Other RNAs are long and must be 
fragmented to smaller sizes, such as *200–250 nt long, to be suitable for sequencing. 
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Once RNAs of the appropriate size are obtained, they are converted into 
complementary DNA (cDNA) by a reverse transcriptase using random primers. 
Adapter oligonucleotides are then ligated to the cDNA to allow amplification and 
enable sequencing. 
For some types of Illumina or SOLiD library preparations the identification of the 
direction of the original RNA strand is possible thanks to the use of specific adapters 
ligated to the 3’ and 5’ ends of RNA. The Helicos Direct RNA Sequencing (DRS) 
technique replaces the adaptor ligation with a poly-A tailing step that modifies the 
RNA fragments directly. Because Helicos DRS directly sequences the RNA it directly 
provides information about strand specificity. 
 
Data Analysis 
Dealing with the amount of data generated by RNA-seq experiments time-consuming 
and challenging.  
Data is most often supplied in FASTQ format. This format contains an ID number for 
each read, the read sequence, and a quality score. There are 2 main stages for 
sequencing data analysis. First, one must remove sequencing artefacts and errors from 
the data set that usually are the presence of the ligation adaptors and low-complexity 
reads. There are publicly available tools that can be used to address these issues 
(Falgueras et al., 2010; Lassmann et al., 2009). Sequencing errors can be removed or 
corrected based on the quality score in order to improve the assembly quality. When a 
large genome is the duty subject, for example the human genome, extremely short 
reads (< 17 nt) may be filtered out prior to alignment. 
At the second stage, the processed data are aligned to a reference genome. The data 
alignment and analysis approach choice depends on the sequencing platform and 
particular RNA-seq application. There are some publically available programs that 
can be freely downloaded and efficiently run by individual laboratories to carry out 
total RNA-seq data analysis. TopHat, a fast splice junction mapper for RNA-seq 
reads, is one of the most commonly used programs (Trapnell et al., 2009). Programs 
such as Cufflinks and Scripture (Guttman et al., 2010) may be used to reconstruct the 
full transcripts, resolve individual variants, and even quantitate expression levels for 
each transcript and gene. Further downstream analysis may include differential 
expression analysis. 
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CAGE-seq 
Cap analysis gene expression (CAGE) is a technique introduced in 2003 as a method 
to determine transcription start sites on a genome-wide scale. The principle on which 
the method is based is the isolation and sequencing of short sequence tags originating 
from the 5′ end of RNA transcripts (Shiraki et al., 2003). Then, mapping the tags to a 
reference genome identifies all the transcription starting sites from which the 
transcripts originated.  
CAGE is able to capture full length RNAs and at the same time avoid rRNA and 
tRNA transcripts. First, poly-A terminated RNAs are reverse-transcibed using an 
oligo-dT primer. Alternatively, a random primer can be used for RNAs without a 
poly-A tail, which may constitute a consistent part of the transcriptome (Cheng et al., 
2005).  
The biotinylation and subsequently capture by streptavidin-coated magnetic beads of 
the 5′ cap structure of RNA/ DNA double-stranded hybrids permits the selection of 
hybrids that contain mature mRNA. A restriction site about 20 nucleotides 
downstream the 5′ end of the full-length cDNA is then created by ligation of a linker 
sequence containing an MmeI recognition site. This produces a short CAGE tag 
starting at the 5′ end of eukaryotic mRNAs (Kodzius et al., 2006). 
Due to their size, sequencing CAGE tags is more efficient at detecting transcription 
start sites than sequencing full-length cDNAs and CAGE tags could also identify new 
transcription start sites or genes. 
In early CAGE experiments many CAGE tags were found only once in a given 
sample. This was caused by the limited sequencing depth of the sequencers. In the 
few last years, the next-generation sequencers allowed to generate millions of tags 
from a low amount of sample thus allowing an accurate estimate of the cellular 
concentration of the RNA molecule corresponding to each CAGE tag. This method is 
called Deep-CAGE. The uniqueness of   
 
Deep CAGE 
High-throughput gene expression experiments based on microarrays (Schena et al., 
1995) and serial analysis of gene expression (SAGE) (Velculescu et al., 1995) give us 
a snapshot of the RNA concentrations in the cell in a specific condition. Quantitative 
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real-time PCR (qRT-PCR) (Heid et al., 1996), can provide a valuable standard for 
validation because of its accuracy and wide dynamic range. The characteristic 
features of CAGE expression profiling make it particularly suitable for investigating 
the transcriptional regulatory network that controls the expression of genes. 
CAGE tag counts allow us to calculate the cellular amount of the corresponding RNA 
molecule directly in digital form, without the need of an analog/digital signal 
conversion phase. Moreover, expression profiling based on tag sequencing is 
unbiased so one mRNA is not preferentially detected over another. This allows a 
direct comparison of the expression values of different genes measured in a single 
deep CAGE experiment. 
In contrast, microarray fluorescence levels are affected both by the probe-dependent 
mRNA affinity and by mRNA: this precludes a direct comparison between genes. In 
addition, tag counts have a dynamic range that is orders of magnitude larger than 
microarray expression levels. The accuracy and the dynamic range of CAGE- and 
SAGE-derived expression levels as well as the sensitivity of detecting lowly 
expressed transcripts have been improved further by deeper sequencing. Importantly, 
methodologies based on tag sequencing can also measure the expression of currently 
unknown transcripts while microarray and qRT-PCR expression profiling need a 
primer pair in order to study a specific transcript. 
CAGE allows us to determine in a single experiment the promoter that regulates the 
transcription of a specific transcript combined with its expression level. 
.Even though the potentiality of this method, the throughput of these CAGE was 
insufficient to allow genome-wide expression profiling and may not be able to detect 
lowly expressed transcripts until the advent of next-generation sequencers.  
Advances in sequencing chemistry have led to innovations such as pyrosequencing, 
Solexa sequencing by synthesis (Illumina, Inc., San Diego, CA, USA), SOLiD 
sequencing by oligo-nucleotide ligation and detection with 2-base encoding (Applied 
Biosystems, Foster City, CA, USA), and true single molecule sequencing by Helicos 
(Helicos BioSciences Corp., Cambridge, MA, USA). 
These sequencers are particularly suitable for short sequence reads, the kind generated 
by CAGE. This makes easier the sequencing of the transcriptome while, in contrast, 
genome sequencing is more difficult because longer sequence reads are preferred. The 
increased throughput of sequencers enables CAGE sequencing at a much deeper 
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scale. This implies that it is possible to detect RNA molecules present at very low-
copy numbers in the cell. 
Deep CAGE also increases the tag count for each particular mRNA: this enables more 
precise expression profiling also for all expressed transcripts.  
The uniqueness of Deep CAGE resides in the capability of detecting both 
transcription start sites as well as their expression level. 
Promoters identification by deep CAGE 
A promoter is a region of the DNA that is located near the transcription starting site of 
a gene, (on the same strand and at the 5’ of the gene). It can be 100-1000 nucleotides 
long and its function is to regulate gene transcription. A promoter contains different 
regulatory elements:  
- the transcription starting site;  
- a binding site for RNA polymerase;  
- general transcription binding sites;  
- specific transcription binding sites. 
Due to the inherent variability in transcription start sites, CAGE tags are typically 
found scattered over short genomic regions. Promoters can be constructed by 
clustering the 5’ ends of the individual CAGE tags based on their position on the 
genome (Carninci et al., 2005). In deep CAGE experiments, transcription start site 
clustering may also take into account the similarity in expression profiles. Deep 
CAGE thus allows us to define the individual promoters and their activity. 
Transcription units in mammalian genomes are characterized by alternative 
transcription start sites and multiple splice forms. These forms could be active in 
different cellular contexts (Carninci et al., 2006; ENCODE and Consortium, 2004; 
Ravasi et al., 2006; Zavolan et al., 2003). CAGE tags can correspond to previously 
identified promoters, or to novel promoters and transcripts that may give rise to novel 
protein variants. CAGE has also led to the discovery of novel noncoding RNAs. 
The analysis of CAGE- defined transcription start sites in human and mouse 
illustrated that promoters characterized by a TATA-box tend to have a clear, single 
transcription start site, whereas promoters associated with CpG islands tend to have 
transcription start sites distributed over a broad area (Carninci et al., 2006). CAGE 
expression profiling, with its ability to localize the promoter as well as determine its 
expression level, is ideally suited to study the regulation of bidirectional promoters 
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(Trinklein et al., 2004), which may be co-regulated by shared transcription factor 
binding sites. Antisense transcripts, which are transcribed in the opposite direction to 
the coding strand, may play a role in regulation via RNA interference as well as gene 
silencing at the chromatin level (Ambros, 2004; Andersen and Panning, 2003; 
Fukagawa et al., 2004; Imamura et al., 2004). A genome-wide analysis of CAGE 
transcriptome data revealed frequent concordant regulation of sense/antisense pairs 
(Katayama et al., 2005). 
A major goal of the analysis of deep CAGE is to infer the regulatory network that 
orchestrates transcription in a cell (Nilsson et al., 2006). This kind of network is 
qualitatively different from current gene-based networks inferred from microarray or 
SAGE expression profiling because each of the promoters may be associated with one 
or more coding or noncoding transcripts. 
Transcription factors 
Transcription factors (TFs) are proteins that mediate transcriptional regulation. TFs 
bind to specific short DNA sequences called transcription factor binding sites 
(TFBSs), which are 5-20 bp in length. These sequences are mainly located in the 
promoters. 
Each TF can regulate multiple genes. A TF can act as an activator, increasing the 
transcription level of the regulated gene, or as a repressor, decreasing its transcription 
level. A TF could act as activator in two main modes: 1) binding to the promoter, the 
TF interacts with the RNA polymerase. This interaction attracts the RNA polymerase 
close to the gene promoter, facilitating its binding to the core promoter. 2) When the 
TF binds the DNA, the structure of the chromatin in the promoter region changes 
conformation and the binding area of the RNA polymerase becomes accessible.  
There are also two main modes of repression: 1) the repressor TF can compete with 
an activator TF on its BS. Therefore, it decreases the effects of the activator, leading 
to less efficient binding of RNA polymerase to the promoter. This obviously results in 
lower expression levels of the gene. 2) The repressor interacts with the same 
components of RNA polymerase as does an activator. By doing this, the repressor 
prevents the activator from interacting with the RNA polymerase.  
TFs bind to short sequences in the promoter. The features of the binding region 
(length and base composition) are dictated by the protein structure of the TF. Though 
the BSs of a TF have a core pattern that is essential for the TF binding, the exact 
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nucleotide composition may vary. This is because some parts of the sequence are 
more important for the binding and thus less subject to viable mutations. The BS 
sequence pattern is called a motif. A common way of representing a motif is by using 
a motif logo. The motif logo illustrates the conserved and variable regions of the motif 
by displaying the information of every position in the motif. 
Prediction of conserved regulatory elements 
In the last two decades, sequence-based computational methods for describing the 
DNA-binding specificities of TFs have been developed and the use of microarray- 
and sequencing-based assays for the high-throughput measurement of protein–DNA 
binding resulted in a burst of motif discovery methods. Most sequence-based DNA 
motif discovery methods use position weight matrices (PWMs) to represent the TF– 
DNA binding specificity (Badis et al., 2009; Bussemaker et al., 2007; Stormo, 2000; 
Stormo and Zhao, 2010). This type of model can be learned from various data types: 
from small sets of known binding sites to high-throughput protein–DNA binding data. 
A different problem arises when looking for motifs (both known and novel, not 
necessary TFBS), enriched in a set of promoter sequences of co-regulated genes.  
The approaches to locate known and novel regulatory elements can be summarized in 
two categories: comparative genomics (Arnold et al., 2012; Lenhard et al., 2003; 
Wang and Stormo, 2005; Xie et al., 2005) and single (or statistical) genomic 
approaches (Bajic et al., 2003; Davuluri et al., 2001; Eskin and Pevzner, 2002; 
Hughes et al., 2000; Kulakovskiy et al., 2010; Pavesi et al., 2007; Sandelin and 
Wasserman, 2004; Sinha and Tompa, 2003; Workman and Stormo, 2000). The first 
strategy, also called “phylogenetic footprinting”, is based on the information coming 
from conservation between orthologous genes regulatory sequence; single genomic 
approaches, on the other hand, look for enriched short signals (typically about 5-15nt 
long) in the midst of a great amount of statistical noise (a typical input being a 
regulatory region of length 500nt-1.5kb). One of the major points that emerged from 
distinct assessments (Das and Dai, 2007; Tompa et al., 2005) that exhaustively 
examined publicly available DNA motif discovery tools, was the difficulty to 
simultaneously achieve balanced sensitivity and positive predictive value, with the 
most serious inaccuracy occurring in non-CpG-related promoters (Bajic et al., 2004). 
In order to have a more accurate representation of the complex interactions associated 
with transcriptional regulation, new approaches look for clusters of TFBS called cis-
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regulatory modules (CRMs) (Bulyk, 2003; Davidson et al., 2002; King et al., 2005; 
Levine and Davidson, 2005; Yuh et al., 1998). CRMs can represent clusters of two or 
more closely associated TFBS for transcription factors that physically interact (Ravasi 
et al., 2010; Sinha et al., 2003). Alternatively, they can describe groups of closely 
associated binding sites for TFs that form macromolecular complexes but do not 
directly bind (Muzny et al., 2006) to each other (Blanchette et al., 2006; Ferretti et al., 
2007), or that are not sufficiently close to directly interact (Kardassis et al., 2002; 
Zhou et al., 2010). Finally, they can represent neighbouring enriched genomic 
elements playing general functional/structural roles (Kolbe et al., 2004; Taylor et al., 
2006) like epigenetic markers, chromatin remodelling sites (Yan et al., 2013) or RNA 
polymerase II stalling-associated sequences (Core and Lis, 2009; Hah et al., 2011). 
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MATERIAL AND METHODS 
 
Human Samples 
Human samples were obtained from the Azienda Ospedaliero-Universitaria of Udine 
and collected after informed consent in accordance with the declaration of Helsinki 
and with approval by the Bioethics Committee. 
Cell Isolation, Culture and Transfection 
N-MSCs were isolated from normal human adult tissues (bone-marrow, heart, and 
adipose tissues) and cultured under uniform conditions as described in Beltrami et al. 
(Beltrami et al., 2007). HG-SOC-MSCs were isolated from primary HG-SOC and 
cultured under uniform conditions as previously described (Bourkoula et al., 
2014)(Beltrami et al., 2007) with minor modifications.  
Surgical biopsies were freshly collected from patients undergoing surgery, washed 
several times in PBS solution and then mechanically disaggregated by mincing it with 
razor blades. Further dissociation was carried out by enzymatic digestion (20µg/ml 
collagenase IV) for 10 minutes at 37º. Single cell suspensions were obtained by 
filtering the disaggregated tissue through a nylon mesh with 70µm pores (Cell 
Strainer, BD Falcon). Recovered cells were cultured in MyeloCult Medium (StemCell 
Technologies) containing 25% of serum (12.5% horse serum and 12.5% of fetal 
bovine serum). When the colonies were formed cells were detached with 0.25% 
trypsin-EDTA (Sigma-Aldrich) and replated at a density of 2.5x103/cm2 onto 
fibronectin (Sigma-Aldrich) coated 100mm dishes (Sacco-Falcon), in an expansion 
medium composed as follows: 60% low glucose DMEM (Invitrogen), 40% MCDB-
201, 1mg/mL linoleic acid-BSA, 10-9M dexamethasone, 10-4M ascorbic acid-2 
phosphate, 1X insulin-transferrin-sodium selenite (all from Sigma-Aldrich), 2% fetal 
bovine serum (StemCell Technologies), 10ng/mL hPDGF-BB, 10ng/mL hEGF (both 
from Peprotech EC). Medium was replaced with fresh one every 3-4 days. 
Peripheral blood mononuclear cells (PBMCs) were isolated from HG-SOC-bearing 
patients through density gradient centrifugation (Biocoll; Biochrom, Berlin, 
Germany). 
MDA-MB-231 and MDA-MB-157 cells were grown in DMEM plus 10% 
tetracycline-free FBS, MDA- MB-468 cells in RPMI 1640 plus 10% tetracycline-free 
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FBS. For transfection of siRNAs, all cell lines were transfected with 100 nM siRNAs 
with Lipofectamine RNAiMAX reagent (Invitrogen). For plasmid, transfection was 
performed with FuGENE (Roche). For the functional rescue experiment, cells were 
first transfected with siRNAs and with plasmid 24 hours later. 
High-Resolution Genotyping Analysis 
Genomic DNA was extracted using QIAamp DNA Mini Kit (Qia- gen, Hilden, 
Germany) and analysed using HumanCNV370- Quadv3_C SNP platform (Illumina, 
San Diego, CA). Copy number information was derived normalizing each tumour or 
each HG- SOC-MSC sample to its matched normal counterpart using B allele 
frequency (BAF) segmentation and crlmm package (Carvalho et al., 2007). 
Real-Time Quantitative RT-PCR 
Total RNA was extracted using the TRIZOL Reagent (Life Technologies, Carlsbad, 
CA) and cDNA was produced using the QuantiTect Reverse Transcription Kit 
(Qiagen). Real-time quantitative RT-PCR was performed using the SYBR Green 
Master Mix (Applied Biosystems, Life Technologies, Carlsbad, CA) on a 
StepOnePlus Real-Time System (Applied Biosystems). 
Gene Expression Analysis 
Total RNA was extracted using Trizol reagent (Invitrogen) subjected to DNase-I 
(Invitrogen) treatment and subsequently column-purified with RNeasy kits 
(QIAGEN). For microarray analysis, four biological mRNA replicates for each group 
(siCTRL or siA1_3) were hybridized on Affymetrix GeneChip Human Genome 
U133A 2.0 array. For quantitative RT-PCR, mRNA was transcribed using Superscript 
II (Invitrogen). Quantitative PCR was performed using SYBR Green PCR master mix 
(Applied Biosystems) and 7500 Real-Time PCR System (Applied Biosystems). 
Low-Level Analysis 
For microarray analysis, three biological mRNA replicates for each group (siHMGA1 
or siControl) were hybridized on Affymetrix hgu133plus2 chips. Cell intensity values 
were computed using the Affymetrix Expression Console. Further data processing 
was performed in the R Computing Environment version 2.14 (http://www.r-
project.org/) with BioConductor packages (http://www.bioconductor.org/). Robust 
Multi- Array Average (RMA) normalization was applied (Irizarry et al., 
2003). Statistical analysis for differentially expressed genes was performed with 
limma (Smyth, 2004). P-values were adjusted for multiple testing using the Benjamini 
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and Hochberg’s method to control the false discovery rate (Hochberg and Benjamini, 
1990). Genes with adjusted p-values below 10-4 and fold change greater than 2.6 (log 
1.4) or lower than -2.6 (-log 1.4) were considered differentially expressed. Gene 
annotation was obtained from R-Bioconductor metadata packages, and the probesets 
were converted in Entrez Gene Id and Symbol Id. 
Hierarchical Cluster Analysis 
Starting from the normalized annotated expression matrix after gene median 
centering, features that had standard deviation of less than 0.3 were filtered out. 
Unsupervised hierarchical cluster analysis (average- linkage method) was performed 
using Cluster software (EisenLab). Cluster results were then visualized using Java 
TreeView. 
For the clustering of functional annotations (average- linkage method), for each 
sample –log(p-values) of enrichment of functional ontologies have been used: 
geodesic distances have been calculated and results were visualised using proxy 
(Meyer and Buchta, 2015) a package for R. 
Functional Analysis 
Differentially expressed gene lists obtained from low-level procedures were analysed 
for functional associations. 
• Data were analysed through DAVID Bioinformatics Resources v6.7 (Dennis 
et al., 2003) using the suggested standard parameters. 
• Data were analysed through Ingenuity Pathway Analysis (IPA) 
(http://www.ingenuity.com) software. Core analysis was performed, and the 
top associated networks table was reported.  
• Data were analysed through the Oncomine (Rhodes et al., 2007) web tool 
using suggested standard parameters. Custom concept analysis was performed, 
and the “Summary view” (adapted) was reported.  
• Data were analysed through ClueGo (Bindea et al., 2009), a plug-in for 
Cytoscape (Shannon et al., 2003) with suggested standard parameters. 
To perform Analysis of Functional Annotation (AFA) a combined dataset of the 
functional analysis results were created, where the significance of each biological 
functional/transcriptional regulators was transformed as the log(p-value). 
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Survival analysis 
Several published gene expression datasets (breast cancer meta-dataset) were 
considered and compared with the gene signatures of interest. The raw data were 
retrieved from the gene expression omnibus (GEO) public gene expression database 
(GSE1456, GSE4922, GSE5327, GSE6532, GSE7390, GSE11121, GSE12093, 
GSE2603, GSE16446, GSE19615, GSE20685, GSE21653). Data were normalized in 
R/Bioconductor environment using the RMA normalization method (affy package), 
creating a breast cancer meta-dataset. Gene annotation was obtained from brainarray 
custom CDF metadata packages, and the probesets were converted to Entrez Gene Id 
and Symbol Id. Each dataset was analysed separately to avoid platform and signal 
merging problems, and only the results were combined together. To evaluate the 
correspondence between the signatures expression levels and breast cancer clinical 
data, we utilized the gene expression-based Outcome for Breast Cancer web tool 
(GOBO) (Ringnér et al., 2011). To verify the correlation of the gene signatures and 
breast cancer clinical data, a Mantel-Haenszel test was applied to the normalized 
meta-dataset (survival R package), and the Kaplan–Meier survival curve of time to 
distant metastasis (TDM) of breast cancer patients classified according to the 
expression of the signatures was obtained. With the same meta-dataset, we searched 
for the distribution of the gene expression intensities of the signatures of interest 
across different breast cancer subtypes (stats R package). 
For the analysis of the mesothelial signature, we performed Kaplan-Meier survival 
analysis considering progression-free survival (PFS) time of ovarian cancer patients, 
relapse-free survival time of breast cancer patients, and first progression (FP) time of 
lung cancer patients. Samples were classified according to the expression of the HG-
SOC-MSCs gene signature (HSM-GS) using KMplotter web tool (Gyorffy et al., 
2012; Györffy et al., 2010a; Győrffy et al., 2013). 
FANTOM5 Genomic sequences 
Globally, 889 human CAGE libraries (495 primary cell samples, 259 cancer cell lines 
and 135 post-mortem tissues) were sequenced at a single-molecule level and 
analysed. RLE-normalized expression values were calculated using edgeR (Robinson 
et al. 2010), providing an evaluation of the number of tags per million (TPM) and 
presenting information on sample-related transcripts relative abundance. A total 
number of 184,827 robust human Sample-Specific CAGE clusters (SSCs) were 
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identified as having greater than or equal to 10.0 RLE-TPM and at least ten-fold 
higher than the median expression of the cluster across all available hCAGE libraries. 
The genomic sequences for these SSCs clusters were extracted after adding 300nt 
upstream and 100nt downstream of each cluster and sample-specific regulatory 
elements were discovered using the software ScanAll. 
Sample Ontology 
Samples were divided into functional groups using a modified version of the Sample 
Ontology developed by a member of the FANTOM5 Consortium (Dr. Tom Freeman, 
University of Edinburgh). 
Differential expression analysis of FANTOM5 data 
The robust transcriptional (RLE) activity peaks count FANTOM5 data matrices (TPM 
or counts) were used for the differential transcriptional analysis (a, b, count Matrix), 
relationship analysis (c, TPM matrix) and correlation analysis (d, TPM matrix). 
EdgeR(Robinson et al., 2010a) package for  R/Bioconductor 
Environment(Gentleman, 2005) was used for statistical analysis. 
a) Direct comparison between HG-SOC-MSCs and N-MSCs. 
We considered genes with a differential transcriptional activity with log fold 
change at least greater/lower than 2/-2 respectively (p<10-5, FDR corrected). 
b) HG-SOC-MSCs and N-MSCs vs. other samples. 
The purpose of this analysis was to obtain specific gene profiles of HG-SOC-
MSCs and N-MSCs with respect to all other FANTOM5 project samples. 
However, it would be totally inappropriate to perform such comparison by 
pooling all the other samples together (for biological and statistical reasons) 
since performing such comparison will bias specific groups of samples. To 
this aim we created 100 randomly selected samples of similar sizes of that of 
the HG-SOC-MSCs (n=9) and N-MSCs (n=10) subsets. After performing all 
the contrasts, we considered only the genes showing a differential 
transcriptional activity (p<10-4, FDR corrected) in at least 90% of comparisons 
between HG-SOC-MSCs or N-MSCs and random samples subsets. The log 
fold change is the average value of all comparison log fold changes.  
c) Relationship analysis. 
We compared HG-SOC-MSCs against all other samples divided in biological 
classes (Class 4_Class1, n=220) with respect to previously described samples 
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ontology, thus obtaining the lists of differential genes. We then ranked the 
biological groups on the basis of the number of differential genes with 
different cutoff of p-values (p<10-10, p<10-15, p<10-20), FDR corrected). The 
biological groups most similar HG-SOC-MSCs  (less than 20 genes) where 
reorganized into biological categories despite the tissue of origin. 
d) correlation analysis. 
MSC samples data was extract from the TPM matrix, log tranformed and 
center normalized. Pearson Correlation matrix among the different MSC 
groups was computed and graphical rappresented using gplots(Warnes, 2010) 
package for  R/Bioconductor Environment(Gentleman, 2005). 
 
Differential gene peak usage analysis 
Starting from the TPM matrix (sample n=889, peaks n=184828), we considered each 
peak active in a sample if the corresponding TPM was greater than 15. The number of 
active peaks for each gene in each sample was then calculated. We then performed the 
following analysis: 
a) Direct comparison between of HG-SOC-MSCs and N-MSCs. 
Since in this analysis we wanted to select genes with differential global peak 
activity, we excluded from the analysis the genes with no active peaks in at 
least 50% of the samples in each group. 
Then we compared the total number of peaks activated in each genes between 
the two the groups using Welch's t test. Finally we considered differential 
genes with at least pValue less than 0.05. 
 
b) Relationship analysis. 
We compared HG-SOC-MSCs against all other samples divided in biological 
classes (Class 4_Class1, n=220) with respect to previously described samples 
ontology, using the same approach used in direct comparison between of HG-
SOC-MSCs and N-MSCs thus obtaining the lists of global peak activity 
analysis. We then ranked the biological groups on the basis of the number of 
differential peaks with p<10-5. The biological groups most similar HG-SOC-
MSCs (less then 200 genes) where reorganized into biological categories 
despite the tissue of origin. 
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ScanAll 
ScanAll is a software composed of three main components: ScanPro, which looks for 
single over-represented motifs in biological sequences; ScanMod, which sub-selects 
only the motifs belonging to composite regulatory elements; the filtering pipeline, 
which sorts only the most functionally informative modules. 
ScanPro 
When starting the analysis, the following parameters were provided: 
- a set of n sequences (the SSCs to be analysed) of length L (not fixed) 
- ℓ, the length of the motif to be found 
- d, the number of mismatches (or variable nucleotides) allowed in each motif 
- q (the quorum), the minimal number of sequences in which motifs are required to 
be enriched 
By examining PWMs databases, the most common length of motif layouts ranges 
from 5 to 12nt, with a number of mismatches between 1 and 3. We decided to fix ℓ to 
6 and d to 1 as they represent the average length/structure of TFBS core sequences 
(the most conserved and biologically meaningful). Moreover, quorum q was fixed to 
150 (corresponding to 10% of the average number of genomic sequences in each 
FANTOM5 sample).  
For an extensive description of ScanPro algorithm and Karp-Rabin algorithm (on 
which ScanPro is based) see Supporting Information. 
ScanMod 
This phase consisted in finding composite regulatory structures, groups of two or 
more closely positioned enriched motifs. No parameter exists for fixing the maximum 
number of modules-composing motifs; hence, very long modules could be potentially 
obtained. As a side effect, this phase was also very useful in reducing the size of 
ScanPro output: by sub-selecting only module-composing motifs, in fact, we were 
also able to define a fraction of ScanPro results that was easier to manage during the 
downstream analysis phases. 
The modules identified were on the form M1 <d,D> M2…<d,D> Mx, and the 
following parameters were provided: 
- Mx, a motif belonging to a list (the ScanPro output) 
- d, the minimum required distance between left-end and right-end of motifs in 
the module 
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- D, the maximum allowed distance between left-end and right-end of motifs in 
the module  
- a set of n sequences (the same input received by ScanPro) 
- q (the new quorum), the minimal number of sequences in which a module is 
required to be enriched 
It was also possible to set a filtering value, the Complexity (C), defining the number of 
different nucleotides appearing into an instance of an input motif. For example, the 
“AACnG” motif might have a “complexity” of either three or four, depending on the 
value of n. If the required complexity is set to four, the motif will equate to 
(AACTG). 
To perform the analysis we fixed d to 40, D to 90, q to 60 and C to 4. 
Filtering 
Modules found by ScanMod were filtered based on a Z-score. The Z-score uses the 
normal approximation to the binomial distribution to compare the rate of occurrence 
of a TFBS in the target set of genes to the expected rate estimated from the pre-
computed background set. For a given TFBS, the random variable X denotes the 
number of predicted binding site nucleotides in the dataset. Let B be the number of 
predicted binding site nucleotides in the background dataset. 
Using a binomial model with n events, where n is the total number of nucleotides 
examined (i.e. the total number of nucleotides in the conserved non-coding regions) 
from the co-expressed genes, and N is the total number of nucleotides examined from 
the background genes, then the expected value of X is u = B * C, where C = n / N (i.e. 
C is the ratio of sample sizes). Then taking p = B / N as the probability of success, the 
standard deviation is given by s = sqrt(n * p * (1 - p)). 
Now, let x be the observed number of binding site nucleotides in the dataset. By 
applying the Central Limit Theorem and using the normal approximation to the 
binomial distribution with a continuity correction, the z-score is calculated as z = (x -
 u - 0.5) / s. Background sequences are generated by shuffling the di-nucleotides of 
the original sequences. Then, for perfectly overlapping modules, that means they are 
different layouts of the same conserved sequence, only the module with the best z-
score is retained. 
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Motifs Annotation 
We proceeded to the annotation of the module-composing motifs using TOMTOM 
(http://meme.nbcr.net/meme/cgi-bin/tomtom.cgi). We queried the TRANSFAC, 
SwissRegulon, JASPAR and UniPROBE human public databases, along with the 
ENCODE cis-regulatory lexicon and the HOMER and HOCOMOCO collections. We 
considered as positive matches all the hits to any of these databases within an E-value 
< 0.5, corresponding to less than 1 hit being expected at random, the remaining results 
constituting our list of putative novel motifs. 
FANTOM 5 Cluster analysis 
The TPM FANTOM5 data matrix (samples n=889, peaks n=184827) was used for 
cluster analysis. After gene median centering, features whose standard deviation was 
less than 0.55 were filtered out, thus obtaining the TPM filtered matrix (sample 
n=889, peaks n= 26266). Unsupervised hierarchical cluster analysis (average-linkage 
method) was performed using the Cluster software (Eisen et al., 1998) and cluster 
results were visualized using Java TreeView (Saldanha, 2004). 
Expressed TFs 
The list of expressed TFs for each biological group was obtained starting from the 
TPM matrix: a TF was considered expressed in a biological class if at least one peak 
associated with that TF had a TPM value >2.5 
Protein-protein interactions 
Interaction data generation from TFs lists was performed using iRefR (Mora and 
Donaldson, 2011), a R package based on the iRefIndex protein-protein interaction 
database (Razick et al., 2008). We considered only Human protein-protein 
interactions data. 
Motifs Mapping to Transposable Elements (TE) 
The ScanMod output was converted in standard BED-6 format. The BEDTools utility 
(Quinlan and Hall, 2010)  was used to compare .bed files containing ScanMod results 
to a file with all the annotated human transposable elements (retrieved from the 
TranspoGene project, http://transpogene.tau.ac.il/index.html). For each module-
composing motif identified in the 38 selected FANTOM5 samples, or in the four 
analysed ENCODE cell lines (HeLaS3, HepG2, GM12878 and K562), we counted the 
number of instances mapping to TEs and to the promoter regions not overlapping 
TEs. The resulting ratios were then compared to the sample-specific ratios obtained 
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by dividing the length of the promoter regions overlapping TE regions by the 
promoter regions not overlapping TE regions, and we considered as over/under-
represented those motifs whose folds were greater than two or smaller than minus 
two, respectively. 
Coding and software implementation 
ScanPro and ScanMod were implemented using C++ language. The R/Bioconductor 
environment (R Development Core Team, 2011) was used to handle filtering, 
functional validation, text manipulation, statistical analysis, graphical representation 
and all the automatic annotation steps. The following packages were used: ade4 (Dray 
and Dufour, 2007), Biostrings (Pages et al., 2013), coin (Hothorn et al., 2006), edgeR, 
ggplot2 (Wickham, 2009), gplots (Warnes et al., 2013), pROC (Robin et al., 2011), 
ROCR (Sing et al., 2005), seqLogo (Bembom, 2013) and Vennerable (Swinton, 
2011).  
Data Access 
The accession number in the Gene Expression Omnibus public database for the 
MDA-MB-231 expression array experiment is GSE35525. 
The full set of sample-specific analysed FANTOM5 promoters regions can be 
accessed as indicated in the FANTOM5 main paper(Forrest et al., 2014). 
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RESULTS 
 
Using high-throughput data to characterise cell lines isolated from healthy and 
cancer tissue 
Cellular models experiments could provide data that permits to focus on specific 
molecular mechanisms and probe the effects of molecules in a specific cancer model. 
It is known that the observations obtained in cellular models can’t always be 
reproduced in the tissue of interest. The reasons of these differences are many: on one 
hand in vivo and in vitro environments interact in different ways with the biological 
process that take place in the cells.  In particular, in vitro experiments do not take into 
account the supporting role of tumour microenvironment. To complicate matters, 
cancer cell lines can’t always be assigned univocally to a specific tissue of origin. 
There are different causes of this fact: 1) the intrinsic plasticity and tendency to 
accumulate mutations of the cancer cell lines; 2) the difficulty of comparing cancer 
cell lines genotypes in respect to healthy tissues genotypes; 3) the intrinsic 
heterogeneity of the cancer tissue; 4) the fact that, for a lot of cancer types, the tissue 
of origin of the cancer cells is not known yet; 5) also observing the same type of 
cancer, different molecular subtypes can potentially originate from different healthy 
tissues. In the next section I describe a publicly available high-throughput dataset that 
includes cancer cell lines, primary cell lines and human tissues, thus making possible 
a direct comparison between cancers derived cell lines and human tissues. 
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The FANTOM5 promoterome atlas 
Although the genome information is the same in almost all cells of an individual, each 
distinct cell type has its own regulatory repertoire of active and inactive genes. Every 
single cell responds to external stimuli and alterations in environment with changes in 
gene expression. Cells interact with other cells in order to perform specific functions 
in the organism. The majority of genes have more than one TSS, and the regulatory 
inputs that determine TSS choice and activity are diverse and complex. Specific sets 
of transcription factors are induced or repressed in each cell line. These transcription 
factors provide regulatory inputs that are integrated at transcription start sites (TSSs) 
to control the process of transcription. Annotation of the regulation, expression and 
function of all the mammalian genes requires systematic analysis of the distinct 
mammalian cell types. It is also necessary to identify the set of TSS in the mammalian 
genome and the transcription factors that regulate their utilization. 
The FANTOM5 project has the aim of mapping the sets of transcripts, transcription 
factors, promoters and enhancers active in the majority of mammalian primary cell 
types. 
During the FANTOM5 project 889 human CAGE libraries were sequenced, providing 
a collection made of 495 human primary cell samples (~150 cell types from 3 
donors), 259 cancer cell lines (representing 154 distinct cancer subtypes) and 135 
human post-mortem tissues. For each sample, several millions of mapped tags (also 
referred to as “peaks”) were generated, clustered based on proximity and subsequently 
subdivided according to their different expression profiles using a method called 
Decomposition-based Peak Identification (DPI; (Forrest et al., 2014)). This allowed 
defining “robust” and “permissive” clusters, based on the number of independent 
single molecule observations (> 10 or > 2, respectively) occurring at least in one 
nucleotide position per library. These peaks account for the majority of known 5’ tags, 
possibly represent transcription start sites and, more generally, provide evidence of 
promoter utilization. In order to distinguish true transcripts from post-transcriptional 
artefacts, robust peaks found in the selected libraries were normalized using the RLE 
method (Anders and Huber, 2010) implemented in edgeR (Robinson et al., 2010b), 
obtaining an evaluation of the number of tags per million (TPM) and providing 
information on sample-related transcripts relative abundance. 
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The FANTOM5 dataset has been critical in different projects in which I am involved. 
One of the main features of the dataset is that it includes samples coming from human 
tissues, primary cell lines and transformed cell lines thus allowing the comparison of 
the cell lines of interest, not only respect to all the other cell lines, but also respect to 
the tissues of the human body. In the next sections of the results the dataset is utilized 
in order to characterize specific cell types that are included in the FANTOM5 dataset.  
 
Mesenchymal stem cells characterization 
Mesenchymal Stem/Stromal cells (MSCs) reside in almost all types of tissues and are 
believed to play a central role in wound repair, tissue regeneration, and maintenance 
of tissue homeostasis (da Silva Meirelles et al., 2006; Uccelli et al., 2008). The 
interactions between mesenchymal and epithelial parenchyma are essential for 
organogenesis and also play a critical role in cancer progression (Hanahan and 
Weinberg, 2011). MSCs are in fact present also in the tumour microenvironment. 
They could be recruited via the blood stream from the bone marrow thus exerting 
multiple and complex roles. In my laboratory it has been previously reported a 
protocol for the derivation of multipotent stromal cells from normal human adult bone 
marrow, heart, liver and adipose tissues (hereafter referred to as N-MSCs) that 
maintain the ability to differentiate along various lineages (Beltrami et al., 2007; 
Zeppieri et al., 2013). The protocol has been adapted in order to obtain mesenchymal 
stem/stromal cells (MSCs) from primary high-grade serous ovarian cancers (HG-
SOC-MSCs) (see Supporting Material Table S1). In breast and ovarian cancers, the 
stromal tissues supporting the tumour mass are composed of cell populations with no 
evident genomic alterations (Qiu et al., 2008), thus originating from normal adult 
tissue stem cells. The genomic status of the HG-SOC-MSCs had been assessed by 
high-resolution genotyping analysis using the Illumina Infinium SNP BeadChips. The 
investigated data set was composed of matching HG-SOC primary tissues, HG-SOC-
MSC cells and peripheral blood mononuclear cells (PBMCs), each triplet from three 
patients. As clearly shown in Figure 1 A and B, no differences were detected between 
PBMC and HG-SOC-MSC genomes, while genome-wide aberrations were clearly 
found between matched PBMC and HG-SOC genomes (p<0.03, paired t-test). In 
order to test for tumourigenicity, cultured HG-SOC-MSCs were injected into NOD-
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SCID mice in parallel to SKOV3. 1x10
6 HG-SOC-MSCs from three separate patients 
were injected subcutaneously in duplicate into mice and followed for 12 weeks. These 
cells were incapable of forming tumours. In contrast, 1x10
6 SKOV3 cells (in five 
replicas) were capable of forming subcutaneous tumours in 2 weeks (see Supporting 
Material Table S2). 
 
 
 
Figure 1: Transformation of B allele frequency data for matched samples. Application of the segmentation 
strategy (BAF estimates) to the matched three samples belonging to the same patient (SOC-43-01): Peripheral 
Blood Mononuclear Cells (PBMCs), HG-SOC whole tumour sample and HG-SOC-MSCs derived from the tumour 
sample independently hybridized on Affymetrix 450k SNP arrays. Top panel shows BAF estimates and the lower 
panel copy number estimates for PBMCs versus HG-SOC-derived-MSCs (A) and PBMCs versus HG-SOC (B).  
Figure 2 
PBMCs vs HG-SOC-MSCs (P1)               PBMCs vs HG-SOC (P1)!
              !
A                                            B!
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Promoter activity analysis of MSCs 
The transcriptional identity of HG-SOC-MSCs was analysed by comparing their 
profiles to the large collection of samples in the FANTOM5 Project. Ten normal 
tissue-derived MSC populations (N-MSCs) obtained from ten different patients (three 
from adipose tissue, three from bone-marrow, and four from heart tissue) and nine 
HG-SOC-MSCs (obtained from four different patients) (Table 1) were profiled by 
deep-CAGE technology (Kanamori-Katayama et al., 2011a) as part of the FANTOM5 
project. In order to analyse the promoter activity peaks in terms of deep-CAGE-
derived expression profiles, I performed differential gene expression analysis using a 
read count-based statistics approach (Robinson et al., 2010a). This kind of approach 
considers each peak as representative of the expression of the related gene. This 
permitted me to identify a list of differentially expressed genes: 625 genes that were 
more expressed in HG- SOC-MSCs and 450 genes more expressed in N-MSCs were 
identified (p-value < 10
-25
, false discovery rate (FDR) corrected) as shown in Figure 
2A set of differentially expressed genes has been experimentally validated by qRT-
PCR analysis, in N-MSCs with respect to HG-SOC-MSCs (in Figure 2B). The 
resulting HeatMap in in Figure 2C shows the agreement between the expression 
analyses based on CAGE-seq peak activity and the qRT-PCR results. These results 
confirm that FANTOM5 peak activity data are representative of gene expression.  
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Table 1: MSC samples. N-MSCs and HG-SOC-MSCs samples used as mRNA source for the deep-CAGE 
sequencing analysis. 
MSC line Sex Age Tissue 
HSLIM-16 F 71 Adipose 
HSLIM-26 F 46 Adipose 
HSLIM-85 F 50 Adipose 
BM-21 M 56 Bone Marrow 
BM-29 F 56 Bone Marrow 
BM-37 M 70 Bone Marrow 
HH-337-AD M 27 Heart tissue 
HH-354-AD M 70 Heart tissue 
HH-394-AD M 57 Heart tissue 
HH-421-AD M 54 Heart tissue 
SOC-19-01 F 47 Serous Ovarian Carcinoma - Left Ovary 
SOC-19-02 F 47 Serous Ovarian Carcinoma - Right Ovary 
SOC-41-01 F 39 Serous Ovarian Carcinoma - Left Ovary 
SOC-41-02 F 39 Serous Ovarian Carcinoma - Right Ovary 
SOC-43-01 F 83 Serous Ovarian Carcinoma - Left Ovary 
SOC-43-02 F 83 Serous Ovarian Carcinoma - Right Ovary 
SOC-57-01 F 63 Serous Ovarian Carcinoma - Left Ovary 
SOC-57-02 F 63 Serous Ovarian Carcinoma - Right Ovary 
SOC-57-03 F 63 Serous Ovarian Carcinoma - Right Ovary 
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Figure 2: Transcriptional signatures of N-MSCs and HG-SOC-MSCs. A) Hierarchical clustering of the peaks 
data generated by deep-CAGE sequencing of HG-SOC-MSCs and N-MSCs for the differentially expressed genes 
(single peak analysis). Red and green bars represent, respectively, up-regulated or down-regulated genes with 
respect to the average of all samples. B) qRT-PCR validation of selected genes differentially expressed between 
HG-SOC-MSCs and N-MSCs. C) HeatMap of qRT-PCR confirmed genes from TPM matrix. 
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Functional characterization of MSCs 
The next step was to compare the HG-SOC-MSCs and N-MSCs deep-CAGE profiles 
with the entire FANTOM5 phase1 dataset, which includes 889 distinct samples. For 
this analysis I used an approach based on the comparison of the cell lines of interest 
against 100 randomly generated datasets (see Materials and Methods). The obtained 
results were subjected to analysis of functional annotation (AFA) (Figure 3). The 
analysis revealed (left panel for functions, right panel for transcriptional regulators) 
that N-MSCs and HG-SOC-MSCs share the activation of common core biological 
functions and transcriptional regulators, the differences residing in the different level 
of their activation. Among the most up-regulated biological themes in HG-SOC-
MSCs versus N-MSCs, the following emerged as significant: cancer-related and 
developmental functional terms (red bar and blue bar, respectively), invasion, 
vasculogenesis, and cell motility (Table 2). The transcriptional regulators analysis 
(including the activation of TGFB, VEGF, and HGF) led to the same conclusion, 
suggesting that globally the differences between HG-SOC-MSCs and N-MSCs are 
more quantitative than qualitative. In the two groups of cell lines similar core 
functions and the same transcriptional regulators are activated, however at different 
levels. The transcriptional identity of HG-SOC-MSCs was also investigated with 
respect to the expression of genes previously reported to be associated with ovarian 
cancer-derived MSCs (Lis et al., 2011; McLean et al., 2011; Spaeth et al., 2009), 
showing an overall gene expression concordance of 75%. Specifically, a significant 
correlation was found for BMP2 and BMP4 (McLean et al., 2011) and secreted 
factors involved in fibrovascular organization (Spaeth et al., 2009), thus enforcing 
their critical functions in the homeostasis of the HG-SOC microenvironment. 
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Figure 3: functional analysis of MSCs. Heat-map showing the results of the annotation of functional analysis 
(AFA) Starting from the genes up-regulated in HG- SOC-MSCs vs. N-MSCs, and in HG-SOC-MSCs or N-MSCs 
vs. 100 random- selected samples datasets, the biological functions and associated transcriptional regulators were 
obtained using the Ingenuity Pathway (IPA) tool and then clustered. Left panel: each block represents a single 
functional theme. Colored vertical bars represent the functional themes that are overrepresented in both the N-
MSCs and HG- SOC-MSCs with respect to the random gene lists, but that are also globally overrepresented in the 
HG-SOC-MSCs with respect to the N-MSCs. Among them, a vast group is composed of terms that are 
predominantly cancer-related (red bar). Another group of functional terms is represented by themes related to 
cellular, tissue and organismal development (blue bar). Right panel: the same analysis was performed for the IPA 
associated transcriptional regulators. Each block represents the single transcription factor activation status, 
predicted by the differential expression levels of its known targets. The bar intensity reflects the statistical 
significance (corrected for multiple testing) of the analysis and the actual value is also plotted in trace line.  
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Category) Functions)Annotation) p2Value)
Predicted)
Activation)
State)
Activation) z2
score)
Cellular Movement cell movement 7.45E-04 Increased 3.036 
Cellular Movement invasion of cells 6.70E-04 Increased 2.212 
Gene Expression transactivation 3.81E-04 Increased 2.067 
Cellular Movement invasion of tumour cell lines 8.87E-03 Increased 2.193 
Cancer Cancer 2.26E-02 Increased 2.2 
Infectious Disease replication of virus 1.93E-02 Increased 2.054 
Organismal Development vasculogenesis 1.41E-02 Increased 2.26 
Cardiovascular System 
Development and Function vasculogenesis 1.41E-02 Increased 2.26 
Cellular Movement migration of tumour cell lines 1.35E-02 Increased 2.292 
Organismal Development development of blood vessel 1.04E-02 Increased 2.262 
Cardiovascular System 
Development and Function 
development of 
blood vessel 1.04E-02 Increased 2.262 
Cellular Movement chemotaxis of tumour cell lines 1.01E-02 Increased 2 
Table 2: Functional annotation of the HG-SOC-MSCs vs. N-MSCs differential genes. List of functional 
annotation terms generated by Ingenuity Pathway Analysis tool associated to genes up-regulated in HG-SOC-
MSCs with respect to N-MSCs. For each term p-Value and Activation z-score is reported.  
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HG-SOC-MSCs Are Close Relatives of Mesothelial Cells 
The FANTOM5 project dataset represents to date the broadest transcription start site-
based atlas obtained from the majority of the mammalian cells and tissues (Forrest et 
al., 2014). Using this comprehensive dataset I had been able to define the 
relationships between the HG-SOC-derived MSCs and the entire set of primary cells, 
cell lines, and tissues (n=889), in search of the closest cell/tissue in terms of gene 
expression. Starting from the TPM matrix (see Materials and Methods), and excluding 
genes with low variance across samples (normalized SD > 0.5), I performed 
hierarchical cluster analysis (Figure 4A). All the samples in the dataset aggregated 
into four major groups: cluster 1 is mainly composed of blood and immune-related 
primary cells; cluster 2 is composed of adult tissues, especially of neuronal origin; 
cluster 3 is mainly composed of mesenchymal tissue/primary cells; cluster 4 is 
composed of cancer tissues/cell lines. HG-SOC-MSCs and N-MSCs are both included 
in cluster 3 (Mesenchymal cluster). Interestingly, comparing the different MSCs 
populations, we noticed that the MSCs derived from heart were the most similar to 
HG-SOC-MSCs (Figure 4B). To find the closest transcriptional relatives of HG-SOC-
MSCs I used a hierarchical sample ontology (modified version of the Freeman 
ontology, hereafter referred to as sample ontology, see Materials and Methods) to 
divide the FANTOM5 samples into biological-related groups (n=220). I then 
performed a pairwise differential expression analysis between the HG-SOC-MSCs 
group and all the other biological groups. The analysis showed that, HG-SOC-MSCs 
are one of the most similar to primary mesothelial cells and several cell types (smooth 
muscle cells and fibroblasts) (Table 3A) hypothesized to derive from mesothelial 
precursors (Rinkevich et al., 2012a). 
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Figure 4: Hierarchical clustering of the core FANTOM5 dataset. A) Hierarchical clustering of the peaks data 
generated by deep-CAGE sequencing of the primary cells and tissues of the FANTOM5 project belonging to the 
phase1 sample dataset (n=889). Red and green bars represent peaks up-regulated or down- regulated with respect 
to the average value of all samples. Colored boxes highlight the four main identified clusters. B) Correlation 
among MSC groups. TPM Data for the different MSC groups (adipose tissue-derived N-MSCs; bone marrow-
derived N-MSCs; heart tissue-derived N-MSCs; High-Grade Serious Ovarian Cancer-derived HG-SOC-MSCs) 
was extracted from the global FANTOM5 TPM matrix. The computed Pearson correlation matrix for all the 
normalized and log fold tranforform TMP peaks was then clustered. 
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)
A B 
mesothelium: mesothelial cells  mesothelium: mesothelial cells  
smooth muscle: coronary , carotid, 
artery brachiocephalic, artery 
pulmonary, artery umbilical, artery 
subclavian, prostate 
smooth muscle: aorta, artery 
brachiocephalic, colon, umbilical vein, artery 
subclavian, internal thoracic artery  
fibroblasts: lymph node, pulmonary, 
heart, choroid plexu, conjunctiva 
fibroblasts: periodontal ligament, heart, 
aortic, gingival 
mesenchymal cells: Whartons Jelly, 
amniotic membrane, N-MSCs, 
hepatic, adipose  
mesenchymal cells: bone marrow, adipose 
precursors, N-MASCs 
stem cells: hair follicle stem cells, 
cord blood  
stem cells: embryonic  
tumour cell lines: serous 
adenocarcinoma                       
mesenchymal tumour cells: lipocyte 
(liposarcoma)                                     
teratoma: peritoneum, sacrococcyx  
tumour cell lines: carcinomas 
(endometrial, mucinous, squamous basal, 
bile duct, hepatocellular, serous, cervical), 
glioblastoma, neuroectodermal tumour. 
 skeletal muscle: skeletal muscle 
Table 3: HG-SOC-MSCs close relatives in FANTOM5 dataset. The most similar samples to HG-SOC-MSCs 
were reorganized into biological categories. A) The list of biological groups that resulted similar to HG-SOC-
MSCs using the single peak activity data. B) The list of biological groups that resulted similar to HG-SOC-MSCs 
using the global peak activity data.  
 
Differential Gene Peaks Usage Analysis Supports the Relationship Between HG-
SOC-MSC and Mesothelial Lineage 
To explore the full potential of FANTOM5 CAGE-seq data, we investigated the 
distribution of the peaks for all genes across their entire length, highlighting that, on 
average, nine peaks are associated to each gene. In 15% of the genes more than one 
peak could be considered active (TPM > 15). The presence of multiple active peaks 
could be an indication of open chromatin status leading to multiple transcription start 
sites. This finding hints to an epigenetic mechanisms of transcriptional regulation 
(Onder et al., 2012). I then investigated the differences of multiple active peaks 
between N-MSCs and HG-SOC-MSCs in order to elucidate if this kind of regulation 
could be important to define the particular transcriptional identity of the MSC derived 
from healthy and cancer tissues. In spite of the presence of a dominant peak, there 
were significant differences when considering the presence of multiple peaks along 
the entire gene length, As shown for two representative genes (Figure 5A and B). I 
identified 203 genes with differential number of active peaks between N-MSCs and 
HG-SOC-MSCs (Supporting Material Table S3A and B). Only a fraction of the 
resulting genes (22%) were highlighted in the previous differential expression 
analysis, unveiling differences not otherwise detected. Finally, differential gene peaks 
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usage data were used to search the cell/tissue similar to HG-SOC-MSCs (see 
Materials and Methods): as shown in Table 3B, this analysis further confirmed the 
evidence that HG-SOC-MSCs are close relatives of mesothelial cells. 
 
 
Figure 5: Example of two genes with differential global peak activity. Starting from the TPM matrix, the TPM 
values of the peaks were plotted across the entire length of each gene. A) a representative gene (SERPINE1) 
having a higher number of active peaks in HG-SOC-MSCs with respect to N-MSC; B) a representative gene (FN1) 
having a lower number of active peaks in HG-SOC-MSCs with respect to N-MSC. Bottom panels show the 
graphical representation of the genomic position and the structure of the genes from UCSC refseq and CCDS 
HG19 tracks.  
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A Specific HG-SOC-MSCs Mesothelial-Related Gene Signature Correlating 
With Serous Ovarian Cancer Prognosis 
Starting from the lists of genes found to be differentially expressed between HG-
SOC-MSCs and N-MSCs, derived from both the differential gene expression analysis 
and the differential gene peaks usage analysis, I performed an exhaustive literature 
search using automated tools (Ingenuity Pathway Analysis tool or molecular 
signatures database (Liberzon et al., 2011)) and manual tools (PubMed, Protein Atlas 
(Pontén et al., 2008)) to search for mesothelial-related genes. Among them, I selected 
six genes previously reported as markers of the mesothelial lineage (CALB2, SPP1, 
KRT7, MSLN, CNN1, and LRRN4) and four mesothelial/mesothelioma-related genes 
(TLR2, FN1, MCAM/CD146, and KRT8) (Barberis et al.; Bidlingmaier et al., 2009; 
Connell and Rheinwald, 1983; Kachali et al., 2006; Kanamori-Katayama et al., 
2011b; Ksiazek et al., 2009; LaRocca and Rheinwald, 1984; Park et al., 2007; Sato et 
al., 2010; Taniguchi et al., 2001; Tigrani and Weydert, 2007) and I generated a HSM-
GS composed of nine genes (CALB2, SPP1, KRT7, MSLN, CNN1, FN1, 
MCAM/CD146, TLR2, and KRT8). The expression of all these genes has been 
confirmed by qRT-PCR (Figure 6A).  
In order to study the specificity of the identified transcriptional signature with respect 
to other types of cancers, I analysed high-throughput gene expression datasets 
(GSE23066 for non- small cell lung cancer, GSE29270 for breast cancer, and 
GSE36474 for myeloma) comparing MSCs derived either from cancerous tissue or 
from the healthy tissue counterpart. As shown in Table 4, the HSM-GS signature is 
unique to MSCs derived from HG-SOC and not other cancers.
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! GSE23066! !! GSE29270! !! GSE36474! !! HG-SOC-MSCs!vs!N-MSCs!
!
Fold!
change! pValue!
Fold!
change! pValue!
Fold!
change! pValue! Fold!change! pValue!
FN1! 2.19% 0.298% NA% 0.445% ,2.73% 0.354% ,26.12*% 0.029%
SPP1! 1.00% 0.589% 1.11% 0.205% 1.28% 0.622% 5.56% 1.43E,11%
CNN1! 1.00% 0.294% NA% NA% ,1.03% 0.085% 12.03% 1.74E,19%
MCAM! 1.01% 0.319% 1.06% 0.597% 1.03% 0.036% 16.70% 1.53E,22%
KRT7! 1.29% 0.971% NA% 0.040% ,1.98% 0.675% 39.14% 2.25E,10%
TLR2! ,1.43% 0.370% 1.05% 0.002% 1.09% 0.003% 90.84% 7.35E,15%
KRT8! 1.70% 0.799% 1.02% 0.391% 1.26% 0.169% 100.62% 7.75E,35%
CALB2! 1.03% 0.067% NA% NA% ,1.22% 0.031% 133.94% 2.47E,08%
MSLN! ,1.00% 0.205% 1.06% 0.303% 1.19% 0.617% 346.65% 1.86E,13%
! ! ! ! ! ! !
*% data% from% differential% peaks% usage%
analysis%
Table 4: HG-SOC-MSCs gene signature (HSM-GS) specificity. Differential gene expression analyses between MSCs isolated from cancerous (lung, breast and myeloid cancers) and the 
corresponding healthy tissues (GSE23066, GSE29270 and GSE36474 datasets). In the table we report for each dataset the fold change and the corresponding p-values of the HSM-GS genes. 
Among the non-ovarian tissue-derived MSCs, only very few HSM-GS genes were differentially expressed between the MSCs derived from the cancerous and the corresponding normal tissue. 
Data from differential expression analysis obtained comparing HG-SOC-MSCs and N-MSCs are also shown in the last column of the Table.  
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I was then interested to see if the HSM-GS derived from HG-SOC-MSCs might 
correlate with ovarian cancer prognosis. I analysed several microarray datasets of 
serous ovarian cancer, to my knowledge encompassing all publicly available SOC 
profiles based on the Affymetrix platform at that time, collectively consisting of more 
than 900 patients (Gyorffy et al., 2012). Kaplan-Meier survival analysis of the 
combined datasets showed that SOC patients with higher levels of the selected genes 
displayed shorter PFS time (p<2.5
-05
), as shown in Figure 6B. To evaluate the HG-
SOC-MSCs gene signature specificity I performed the same analysis on several breast 
cancer microarray datasets comprising more than 2,500 patients (Györffy et al., 
2010b) and several lung cancer microarray datasets comprising more than 700 
patients (Győrffy et al., 2013). Interestingly I observed that breast cancer patients 
expressing higher levels of the HG-SOC- MSCs gene signature displayed longer PFS 
time (p<7.1
-05 in Figure 6C), while lung cancer patients did not show significant 
correlation between the HSM-GS gene signature and FP survival time (p=0.06 in 
Figure 6D). Different performances of the HG-SOC-MSCs signature in different kind 
of tumours suggest that the genes included in the signature have a specific role in 
serous ovarian cancer. This specificity could reflect a specific interplay between 
cancer cells and the tumour micro-environment. 
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Figure 6: A) qRT-PCR analysis of HG-SOC-MSCs mesothelial marker genes and selected mesothelial-related 
genes. Relative expression levels in HG-SOC-MSCs with respect to N-MSCs. All the genes are significantly over-
expressed (at least p<0.05) in HG-SOC-MSCs with respect to N-MSCs. B) Survival curves are shown for serous 
ovarian cancer patients with high (red) and low (black) expression of the selected gene signature. PFS time (PFS< 
96 months) has been selected as clinical outcome. Hazard ratio and significance are also reported. SOC patients 
expressing higher levels of the selected genes in tumours displayed shorter progression free survival time (p=2.5-
05). C) Survival curves are shown for breast cancer patients with high (red) and low (black) expression of the 
selected genes. PFS time (PFS< 96 months) has been selected as clinical outcome. Hazard ratio and significance 
are also shown. Patients expressing higher levels of the selected genes in tumours displayed longer progression 
free survival time (p=7.1-05). D) Survival curves are shown for lung cancer patients with high (red) and low (black) 
expression of the selected genes. FP time (FP< 96 months) has been selected as clinical outcome. Hazard ratio and 
significance are also shown. Patients expressing higher levels of the selected genes in tumours displayed no 
significant change in first progression survival time (p=0.06). 
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Mesenchymal stem cells characterization final remarks 
I analysed the identity of HG-SOC-MSCs respect to the vast panel of tissues and cell 
lines included in the FANTOM5 dataset. Taking advantage of deep-CAGE 
sequencing I have been able to show that HG-SOC-MSCs possess distinct and 
specific CAGE-peak promoter activities with respect to N- MSCs. Among all the 
FANTOM5 samples, both gene expression and gene peak usage analysis results 
suggested that HG-SOC- MSCs were close relatives of mesothelial cells, and their 
derived mesothelial-related signature is correlated with bad prognosis in ovarian 
cancer. All the results have been published (Verardo et al., 2014). 
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Create new tools to discover regulatory elements in the human genome 
The FANTOM5 dataset includes information about the transcription starting sites in a 
wide range of human tissues and cell lines. This is very useful not only to evaluate the 
expression of the genes, but also to specifically study the activity of their promoters 
and the fine regulatory network that drives gene expression. Every experiment 
represents a set of genes that are co-expressed in a specific tissue or cell line and it is 
very likely that co-expressed genes share common transcriptional regulators. Because 
of the fact that we know the position of each transcription starting site (TSS), we are 
able to define a set of sequences that are included in the promoters of a set of co-
expressed genes. In order to find the transcriptional regulators that are able to bind 
such promoter sequences and regulate genes, me and my research group developed a 
de novo motif discovery software: ScanAll. The main feature of this software is that it 
is able to find modules (combinations of motifs) that are enriched in a set of 
sequences. In the following sections I will show the results obtained by analysing the 
FANTOM5 dataset using ScanAll.   
 
ScanAll working pipeline 
We used our newly developed software ScanAll on the genomic regions surrounding 
the peaks of the FANTOM5 dataset to discover sample-specific motifs and composite 
regulatory modules (Figure 7). ScanAll is a software composed of three main 
components: ScanPro, which looks for single over-represented motifs in biological 
sequences; ScanMod, which sub-selects only the motifs belonging to composite 
regulatory elements; a final Filtering phase, which retains only the most significant 
modules. 
During the ab initio motif discovery phase we fixed ScanPro motif length ℓ=6 and the 
number of mismatches d=1, in order to account for the most common structure/length 
of the core sequence of a TFBS (see Discussion and Methods for more details). This 
variation is prevented from occurring in the first position of the element and the 
number of different nucleotides appearing into a motif (Complexity, C) is set to four. 
ScanMod then processed these motifs, generating modules that are combinations of 
motifs. There is no limit to the number of motifs that can compose a module, so 
potentially, ScanMod can find modules composed by any number of motifs. Despite 
this absence of limitations ScanMod has not found modules composed by more than 
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three motifs in any sample. The next step is the statistical validation and filtering of 
the modules. To do so we compared our results respect to the results obtained 
analysing ten randomly generated datasets. The random datasets have been obtained 
shuffling the di-nucleotides of the original dataset. This approach permits us to obtain 
random datasets that, respect to the original FANTOM5 dataset, have the following 
features: 1) the datasets have the same number of samples respect to the original 
dataset 2) each specific sample has the same number of sequences respect to the 
original sample 3) each sequence has the same length respect to the original sequence 
4) each sequence has the same di-nucleotide composition respect to the original 
sequence. This approach not only permits to have a reliable background, but also 
prevents the creation of low complexity sequences in the random datasets. Even 
though ScanAll does not directly filter out low complexity sequences, we set the 
minimum complexity of motifs to four. 
 
 
Figure 7: ScanAll pipeline. Block diagram describing the different steps of the ScanAll pipeline. Starting from 
the FANTOM5 genomic sequences derived from Sample-Specific CAGE clusters, the ScanAll pipeline proceeds 
through 3 phases: ScanPro, the motif-finding step; ScanMod, the module-finding step; the filtering step.
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Motifs and cis-regulatory modules discovery 
Globally, ScanAll identified 580773 unique modules, with more than two thirds of the 
results displaying combinations of two motifs, the remaining composed of three 
motifs and none made of a higher number of motifs.  Looking into more detail to the 
composition of these enriched modules, they were generated by the association of 
2822 non-redundant motifs. The identified enriched elements localise only to specific, 
well-defined sub-regions of the examined promoters. Notably, the positions of the 
modules on the promoter regions are not completely random respect to the 
transcription starting sites (Figure 8). The frequency of modules is low in the portion 
of the promoter that is close to the transcription-starting site. This could be possibly 
due to the presence of low complexity sequences, such as TATA box. 
 
 
Figure 8: figure showing the position of the modules derived motifs found by ScanAll respect to the 
transcription starting site. The number of motifs is divided by the number of sequences that cover that position. 
The grey scale shows the number of sequences ending in that specific position. The low number of motifs in the 
first hundred positions is due to the fact that modules are composed by motifs with a distance constrain (40-90 
nucleotides); because of this in the beginning and in the end of sequences the probability to find modules is lower. 
 
Considering the distribution across samples of the number of motifs and motif 
instances (Figure 9A and B), we found that the majority of samples displayed less 
than two hundreds of different motifs. We then considered the distribution of modules 
across the samples (Figure 9C and D). In this case we can observe that a high number 
of modules are found in only one sample, indicating that our modules are possibly 
regulatory elements with high specificity for a particular cell line or tissue. 
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Figure 9: Distribution of the number of motifs and modules. A) Distribution of motif instances across samples. B) Distribution of motifs in 
samples. C) Distribution of the number of modules in which the same module has been found. D) Distribution of the number of modules in each 
sample.  
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Annotation of cis-regulatory modules 
To define the TFs putatively able to bind these sequences, the module-composing 
motifs were independently annotated with the TOMTOM tool (Gupta et al., 2007). 
Hits were retained within an E-value < 0.5 to human known TFBS in the TRANSFAC 
(Matys et al., 2006), SwissRegulon (Pachkov et al., 2007), JASPAR (Bryne et al., 
2008) and UniPROBE (Newburger and Bulyk, 2009) public databases. Data from the 
ENCODE cis-regulatory lexicon (Neph et al., 2012), the ChIP-seq derived HOMER 
motifs (Heinz et al., 2010) and the HOCOMOCO collection (Kulakovskiy et al., 
2013) was also used. The outcome resulted in 2117 motifs (75% of the total number 
of module-composing motifs) that were associated with a known TFBS, the remaining 
705 (25%) being without any correspondence. There can be several reasons for this 
result but the most likely are on the one hand the possibility that part of the motifs 
composing these modules are highly enriched structural elements but not TFBS, and 
on the other hand that they represent uncharacterized binding sites whose function 
still needs to be defined. In fact, although these motifs were not annotated using 
TOMTOM, MACRO-APE (http://autosome.ru/macroape/) allowed to co-cluster 70% 
of them with novel motifs predicted by other FANTOM5 methods (DMF (Marchand 
et al., 2011), HOMER and ChIPMunk) or identified by the ENCODE Consortium. 
Moreover, the remaining 30% co-clustered with other ScanAll annotated motifs, this 
possibly indicating their status of biologically relevant sequences and, more 
specifically, suggesting a role as novel TFBS. The transcription factors binding sites 
identified by our method and the integration with the other motif findings methods 
used during the FANTOM5 project, had been recently published on Nature (Figure 
10) (Forrest et al., 2014). Interestingly, we observed that the totally unknown modules 
were significantly enriched in samples obtained from tissues with respect to cell lines 
and primary cell specimens (P-value < 10-11, Chi-squared test), with central nervous 
system and gastrointestinal tract samples being among the major contributors to this 
category. 
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Figure 10: De novo derived, cell-state-specific motif signatures. The de novo motif discovery tools DMF, 
HOMER, ChIPMunk and ScanAll were applied to detect sequence motifs enriched in the vicinity of sample-
specific peaks; a), yielding 8,699 de novo motifs; b). The coverage of known motif space by the de novo motifs 
was evaluated by comparing them to the SWISSREGULON, HOCOMOCO, TRANSFAC, HOMER, JASPAR, 
and ENCODE LEXICON motif collections; c)The remaining 1,221 de novo motifs that were not similar to known 
motifs were then clustered using MACRO-APE, resulting in 169 unique novel motifs. 
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Regulatory Modules Compendium 
Afterwards, we analysed the distribution of modules across samples (Figure 9C) and 
the number of different modules found in each sample (Figure 9D) and we found that 
they originated mainly from small, well-defined groups of samples. 
Only a small number of modules (1155 modules, representing 0.2% of the total 
number of modules) are present in more than a hundred samples: the more common 
module is AGCTGN, AGCTGN, found in 431 samples. Interestingly, this module is 
composed by two copies of the same motif, that is associated to TFAP4, an helix-
loop-helix protein that can form homodimers and contains multiple protein-protein 
interfaces (Hu et al., 1990). 
 
We decided to collect all our findings and create a compendium that could be useful 
in order to easily access information about regulator modules in each specific tissue or 
cell line. We started considering all the 580773 ScanAll identified modules: we 
collapsed all the modules holding the same TOMTOM annotation, obtaining a list of 
86390 group-specific TF modules. They were subsequently filtered to retain only 
those expressed (>2.5 TPM) in the specific functional groups, generating an 
Expressed TFs module Compendium containing 26741 elements (22136 for >5 TPM). 
Finally, since Expressed TFs modules describe the particular condition in which two 
TFs are expressed and putatively able to bind to nearby regions in the same promoter, 
we identified couples of TFs that could establish protein-protein interactions (PPI), 
obtaining what we called the PPI Expressed Compendium. Figure 11A and B show 
respectively an example of the Expressed TFs module Compendium and PPI 
Expressed Compendium for a thyroid tissue sample. The composition across samples 
of the Compendium TFs is variable, accounting for the different roles played by 
widely expressed (possibly housekeeping) or group-specific factors. However, what 
impressively characterizes our results is the combinatorial effect of Compendium TFs, 
as it allows underlining very specific regulative modules that would be lost 
considering each TF separately. 
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Figure 11: Example of the Expressed TFs module Compendium A) and PPI Expressed Compendium; B) for a 
thyroid tissue sample. TFs are represented as nodes. In A edges indicate the presence of a module between two 
TFs expressed in that specific sample. In B edges indicates the presence of a module between two expressed TFs 
that can interact at protein level.  
 
Functional analysis 
The Compendium can be used to describe factors that could perform housekeeping 
functions, or that play a specific role in gene regulation in every cell line or tissue. In 
order to delve deeper into the biological functions that are regulated by the TFs 
included in our compendium we performed functional analysis starting from the list of 
TFs that form modules in each biological group, using ClueGo, a function enrichment 
tool for Cytoscape. 
We then tried to understand if the functional enrichment analysis results were 
consistent when comparing the functions performed by every specific tissue. To do 
so, using the functional enrichment information, we performed unsupervised 
hierarchical clustering of every biological class. As shown in Figure 12, groups of 
samples that are biologically related, such as blood and brain samples, are clustered 
together.  Despite the good results obtained for this specific groups of tissues and cell 
lines, it has not been possible to cluster all the tissues and cell lines in a satisfactory 
manner. The reasons of this are probably many: 1) Functional annotation of TFs is 
partially biased by the nature itself of these genes. Each TFs is involved in different 
biological functions and probably it plays more important roles not yet well defined or 
discovered. This observation could be more important in the light of our results. Our 
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analysis revealed that the regulatory specificity in each tissue is controlled by the 
specific combination of TFs. So, the functional annotation of single TFs probably 
can’t give us enough information about the biological functions performed by the 
gene. 2) Cancer cell lines seem to be totally different from their healthy tissue of 
origin. The dataset contains healthy tissues, primary cell lines and transformed cell 
lines. This analysis clearly evidences that cell lines cluster together with other cell 
lines, despite of their tissue of origin. We can suppose that the differences between 
different tissues are not conserved in the derived cell lines. 3) It’s difficult to define 
the active functions in a specific tissue or cell line. We do not have enough 
information to define which biological functions should be active in a specific tissue 
or cell line. From a semantic point of view, the terms included in the gene ontology 
could be biased by the type of tissue or cell line in which a certain gene or process had 
been studied.  
Taking into account all these results, we can say that the combination of TFs that can 
bind our modules in every specific sample could be linked to specific biological 
functions. These functions are shared between samples coming from the same tissue 
of origin in the case of Brain and blood samples. Despite these particular cases, the 
cell lines share biological functions between them and probably lose specific 
functional traits that are characteristic of their tissue of origin. 
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Figure 12: hierarchical clustering of functional annotation. All the samples included in the FANTOM5 dataset 
have been clustered based on the functional annotation of the modules TFs found by ScanAll. Brain and blood 
samples cluster together while cancer cell lines do not cluster close to their tissue of origin. 
 
Association with Transposable Elements 
There is increasing evidence (Brosius, 2003; Johnson et al., 2006; Laperriere et al., 
2007) associating the presence of binding regions to transposable elements. Given the 
fact that a portion of ScanAll motifs could not be coupled to any known TFBS, we 
decided to verify the degree of correlation existing between the modules-composing 
motifs identified in the subset of samples also analysed in the ENCODE project 
(Wang et al., 2012) and the genomic Transposable Elements (TEs). We investigated 
on the one hand if transposition events could have spread specific binding sites across 
the mammalian regulatory regions and on the other hand if motifs themselves could 
be enriched structural elements enhancing transposition. 
As a general feature, we observed that only a small fraction of promoters overlapped 
known TE regions. This, however, was somehow expected considering that in the 
analysed human transposable elements database (retrieved from the TranspoGene 
project, (Levy et al., 2008)) only 9% of the genes (1772/20114) had TEs associated 
with their promoting regions. Nevertheless, we observed that in the samples in which 
more than two different promoters overlapped TE regions, the motifs found in TE 
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regions were over- or under-represented with respect to non-TE regions (P-value < 
0.05, permuted rank tests, multiple correction applied). 
We decided to focus firstly on the HeLaS3, HepG2, GM12878 and K562 cell line 
samples profiled during the FANTOM5 project, as the ENCODE Consortium already 
analysed them to find binding sites enriched in TEs. Our results showed there were 
indeed significant correlations (Figure 13), finding one and three motifs being 
respectively over- and under-represented in TEs in at least two cell lines. Moreover, 
six other motifs displayed opposite behaviour depending on the cellular context, while 
65 had a lineage-specific occurrence, eight being found only in HeLaS3 (three over- 
and five under-represented), four only in HepG2 (three over and one under), 23 only 
in GM12878 (12 over and 11 under) and 30 more only in K562 (14 over- and 16 
under-represented). 
Interestingly, the ENCODE Consortium results provided supporting evidence 
regarding the spatial association we found in HepG2 TEs between MAFB and 
NFE2L2 binding sites, as well as for the presence of JUN sites; besides, we also 
confirmed the mapping of ESR1 sites to transposable elements, as previously seen in 
MCF-7 cells (Bourque et al., 2008; Polak and Domany, 2006). On the other hand we 
could not verify the association between CEBPB, STAT1 and JUN sites, found by the 
ENCODE Consortium in HeLaS3 and HepG2 cells, as we co-mapped them only in 
GM12878 cells, where they displayed an opposite behaviour being under-represented 
in TEs. 
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Figure 13: Motifs overlapping TE regions in the twelve ENCODE cell line samples. The table represents the 
Z-score of the number of motifs overlapping TE regions with respect to the total motifs. For each sample, values 
were normalized for the proportion of promoters covered by TE regions (in base pairs) with respect to promoters 
not covered by TE regions. Values are separately showed for each motif and for each sample. 
Motifs Annotation
CNhs12325 CNhs12326 CNhs12327 CNhs12328 CNhs12329 CNhs12330 CNhs12331 CNhs12332 CNhs12333 CNhs12334 CNhs12335 CNhs12336
GCTCAN ZNF691 4.44 13.45
TTNCAG UW.Motif.0494 2.55 8.28 2.62
TGGCNA RFX1 2.76 4.66
CAGTGN ZBTB3 4.71 2.33 2.16 2.04
ANCCTG UW.Motif.0363 3.08 2.35 82.69 84.34
AGCTGN TFAP4 2.53 2.37 83.26 83.55 82.06
AGNCCT UW.Motif.0435 82.34 83.53
CTGNGA UW.Motif.0480 82.69 82.01
CTNGGA STAT4 82.72 82.10
TNCCAG HAND1 83.05 82.75 83.66 82.99 86.64 82.71 82.18
CTGGNA HAND1 83.73 82.95
CTGNAG UW.Motif.0627 84.12 82.83 82.75 82.88 84.48 83.74 82.09
AGNCTG UW.Motif.0012 83.09 85.51
TGCAGN UW.Motif.0515 85.01 83.81
TCAGGN ESR1 9.59 10.35 815.25 84.78
CTNAGG STAT6 3.85 4.41 4.17 83.58 87.12
GCTGAN MAFB 2.94 3.04
GCTNAG NFE2L2 2.57 2.04
CAGNCT UW.Motif.0012 2.03 2.07
GAGCTN nomatch 83.64 82.06
CTGGAN SMAD3 88.07 811.48 86.94 83.28 82.06 82.80
CAGNGT UW.Motif.0235 4.44 7.89 7.08
AGNTGC NHLH1 4.65 3.76 82.07 83.47
CTCANG FOSL2 2.92 5.16
GANGCT nomatch 3.65 3.65
TGANCC RXRA 2.08 4.45
AGACTN nomatch 3.02 3.50
TGAGCN nomatch 2.11 4.77 2.40
GNCTCA JUN 2.93 3.10
TGNCCA UW.Motif.0045 2.33 3.72 2.54
CACTGN ZNF691 2.13 3.09
TNCTGA REST 2.16 2.19 2.62
GNCTGA PAX5 2.35 2.23
CNTCAG MAFB 2.10 2.03
CANGTG TFE3 82.54 82.05 82.25 2.98 3.03
TGNAGC nomatch 82.58 82.06
CTNAGA STAT5B 82.13 82.55
TCAGNC PAX5 82.19 82.03 83.09
GCANCT NHLH1 83.04 82.08
TCTGAN nomatch 82.24 83.49
TGNGCA CEBPB 82.67 83.19
TCAGNA REST 83.54 82.65
TNTCAG UW.Motif.0118 83.99 82.49 83.29
GANCTG UW.Motif.0229 85.14 82.11
CCTNAG STAT6 85.42 87.03 813.43
CCTGAN THA 87.20 810.61
CNAGTG UW.Motif.0221 7.88 10.33 7.15
GACNTC JUN 6.54 5.19
GNCAGT MYBL1 6.30 3.61 4.24
CNAGGT RORA 3.42 3.90 4.64
TGGCAN TLX1 4.32 3.12
TCNGGA nomatch 6.30 2.73 2.01
CCANGT ATF6 2.73 3.63
GACCTN RARA 2.27 3.03 3.42
CTGACN MAFB 2.10 3.40 2.75
TGGNCA UW.Motif.0045 2.54 2.42
AGANCT UW.Motif.0229 2.07 2.63 2.48
CNAGCT NR2E3 2.23 2.48
CCAGNT TFCP2 2.26 2.26
CTGANT UW.Motif.0625 2.30 2.05
CAGCTN TGIF2 82.61 82.06
CACNTG TFE3 82.05 82.85
AGCTNC UW.Motif.0218 83.06 82.22
CTGAGN PAX5 82.32 83.36
GNTGCA CEBPB 82.48 83.34
CAGTCN nomatch 83.53 83.41
TNAGGC TFAP2A 82.83 84.12
TCNGAG nomatch 84.16 82.66 83.64
AGCCTN UW.Motif.0205 82.68 84.34
TCANGG RARG 82.15 85.52
TCCAGN nomatch 83.36 85.60 85.25
CTCAGN PAX5 87.32 83.56 84.92
TGNCAG UW.Motif.0028 87.06 84.23
GAGNCT nomatch 84.86 88.06
CTGANG MAFB 84.38 89.48
HeLaS3 HepG2 GM12878 K562
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Ongoing research: The complete module atlas of the human genome 
During my PhD project I found the regulatory modules using the information coming 
from the FANTOM5 dataset. In particular, the analysis focused on finding modules 
that were shared between the promoters that were active in a specific sample. The 
dataset included different tissues and cell lines, and only rare and really specific 
tissues (such as embryonic tissues) are not included. We can really think that the 
promoters found in this work are the majority of all the promoters in our genome. The 
next step is to use ScanAll to analyse the entire promoterome, without taking into 
account of which promoters are active in each sample. This approach will permit to 
find genomic elements that are conserved in the promoters of human genome. These 
elements are not necessary linked to regulation of transcription through TFs binding, 
in fact some of them could represent structural elements or have not yet characterised 
functions. 
 
To do so we collapsed all the human samples in a single FASTA file that virtually 
contains all the human promoters found in the FANTOM5 project. We ran ScanAll 
with the same parameters as the previous analysis obtaining the list of conserved 
modules. 
 
We then wanted to define the relationship between the found modules and the peaks. 
To do so we performed unsupervised hierarchical clustering of the modules. This 
analysis is computationally intensive: the matrix is composed by ~420000 rows 
(modules) and ~65000 columns (peaks). We are actually trying different approaches 
in order to overcome this problem. 
 
The first approach is based on the possibility to simply dividing and parallelising the 
process, although any tools seem to not solve our particular problem. 
The second approach is based on the possibility to filter the data in order to reduce the 
size of the matrix and consequently the computational weight. The filtering could be 
done for both modules and peaks. In the case of modules, we can filter out all the 
modules with a low variance for the number of instances in each peak. Filtering the 
modules could be prone to bias because of two reasons: 1) We can’t establish a priori 
which level of variance should be considered as a cut-off; 2) This could lead to the 
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exclusion of housekeeping modules (if they exist); 3) This could lead to the exclusion 
of very specific modules that we found only in few peaks. Despite these limitations, 
taking into account the fact that we want to found the most important modules that 
define a specific group of peaks, this approach is acceptable. 
 
On the other hand, filtering the peaks based on the variance of their expression could 
be a successful approach. We know the expression level of the peaks in each sample, 
so excluding the peaks that do not change between samples is licit. This will also lead 
to the exclusion of all the modules that are found only in those specific peaks. It could 
also be interesting to analyse separately all the peaks that have really low change in 
expression levels in different samples, because of the fact that we can consider them 
as housekeeping transcription starting sites.  
We think that the filtering approach will permit us to perform the clustering and 
associate groups of samples directly to the peaks and so, also to the samples. 
Ongoing research: Build regulatory interaction networks for every specific 
human tissue 
The possibility to assign regulatory modules to specific genes is even more intriguing 
in the prospective of creating tissue specific regulatory networks. It is possible to use 
directed graphs to represent regulatory interactions (Arda et al., 2010). In gene 
regulatory networks (GNR) regulators and targets are represented as nodes and the 
interaction between them as edges. These networks could be useful to explain the 
dynamics and organization principles of gene expression.  
 
Our compendium already includes a section representing the interaction networks 
between transcription factors, where an edge indicates the presence of a module 
composed by the two linked TFs or Unknown motifs (represented as nodes). The 
direction of the edges represents the order of the TFs or motif in modules. 
From preliminary data we observed that in a not negligible number of samples the 
hubs with higher degree are specific Unknown motifs. These motifs are likely to be 
not yet characterised TFBS or structural elements that play a role in gene expression 
regulation. 
We are still working on the representation of networks including also the regulated 
genes.  
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Taking into account all the possible regulatory interactions between TFs and genes, 
network analysis could help to identify specific regulation circuits that are shared 
between samples or that are specific for certain tissues. 
 
Ongoing research: Investigate cancer and cancer related cell lines in FANTOM5 
dataset 
The FANTOM5 dataset is not a cancer samples dataset; in fact, it contains also tissues 
and primary cell lines. This feature makes it particularly suitable for comparing 
cancer cells against healthy tissues. I already performed an intensive analysis 
comparing MSCs coming from HG-SOCs against MSCs coming from healthy tissues; 
besides, the dataset includes also MSCs coming from HG-SOC metastasis. I 
performed differential expression analysis and enlighten the presence of genes that are 
differentially expressed between MSCs from HG-SOC and from metastasis. 
Functional annotation performed using IPA indicates that the genes differentially 
expressed are linked to Inflammation and Immune system (Table 5).  
Furthermore, upstream regulation prediction by IPA indicates progesterone as 
possible responsible for the specific expression pattern seen in metastasis MSCs, 
while inflammatory cytokines seem to revert the observed transcriptional program 
(Table 6).  
 
The next step will be to integrate specific comparison between cancer related cell 
lines and healthy tissues with regulatory modules information coming from our 
Compendium, thus making possible to enlighten the regulatory component of specific 
expression patterns relevant for cancer processes. 
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Table 5 
Metastasis'MSCs'vs'HG-SOC'MSCs''
Canonical'Pathways' '-log(p-value)' Activation' z-
score'
Granulocyte,Adhesion,and,Diapedesis, 15.80, ,,
Agranulocyte,Adhesion,and,Diapedesis, 14.10, ,,
Hepatic,Fibrosis,/,Hepatic,Stellate,Cell,Activation, 11.20, ,,
Inhibition,of,Matrix,Metalloproteases, 6.85, ,,
Role,of,ILJ17A,in,Arthritis, 6.38, ,,
Atherosclerosis,Signaling, 6.14, ,,
Role,of,ILJ17A,in,Psoriasis, 6.02, ,,
Cholecystokinin/GastrinJmediated,Signaling, 5.79, J0.54,
Role,of,ILJ17F,in,Allergic,Inflammatory,Airway,Diseases, 5.33, ,,
HMGB1,Signaling, 4.89, J0.54,
Role,of,Cytokines,in,Mediating,Communication,between,Immune,Cells, 4.44, ,,
TREM1,Signaling, 4.15, J1.27,
Role, of,Macrophages,, Fibroblasts, and, Endothelial, Cells, in, Rheumatoid,
Arthritis, 4.07, ,,
Leukocyte,Extravasation,Signaling, 4.05, 1.29,
LXR/RXR,Activation, 3.60, 2.11,
Acute,Phase,Response,Signaling, 3.28, 0.30,
Role, of, Osteoblasts,, Osteoclasts, and, Chondrocytes, in, Rheumatoid,
Arthritis, 3.07, ,,
Bladder,Cancer,Signaling, 2.96, ,,
ILJ17,Signaling, 2.89, ,,
Airway,Pathology,in,Chronic,Obstructive,Pulmonary,Disease, 2.89, ,,
Role, of, Pattern, Recognition, Receptors, in, Recognition, of, Bacteria, and,
Viruses, 2.85, J0.45,
Regulation,of,Cellular,Mechanics,by,Calpain,Protease, 2.85, 2.00,
Communication,between,Innate,and,Adaptive,Immune,Cells, 2.83, ,,
Prostanoid,Biosynthesis, 2.72, ,,
ILJ6,Signaling, 2.63, J1.00,
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Table 6 
Metastasis'MSCs'vs'HG-SOC'MSCs'
Upstream'Regulator'
Log'
Ratio' Predicted'Activation'State' Activation'z-score' p-value'of'overlap'
HOXB3, 3.33, Activated, 2.00, 3.19EJ06,
FBXO32, 2.00, Activated, 2.16, 7.76EJ10,
NR3C1, 1.96, Activated, 2.15, 7.57EJ10,
PTGS2, J2.03, Inhibited, J2.03, 1.42EJ08,
CSF2, J2.22, Inhibited, J2.58, 1.31EJ09,
HGF, J3.45, Inhibited, J2.21, 7.05EJ18,
IL1B, J4.92, Inhibited, J2.37, 1.08EJ22,
IL17F, ,, Inhibited, J3.08, 2.71EJ15,
progesterone, ,, Activated, 2.22, 5.20EJ12,
peptidoglycan, ,, Inhibited, J3.39, 2.51EJ11,
TLR5, ,, Inhibited, J3.08, 3.48EJ08,
TLR3, ,, Inhibited, J2.98, 4.47EJ08,
TLR4, ,, Inhibited, J2.61, 1.90EJ07,
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Using gene expression cancer datasets to define the role of genes in cancer 
A variety of gene expression cancer datasets are publically available and can be 
investigated in order to find new biomarkers, extracting relevant genomic information 
and validating biological hypotheses. For large cohorts of patients clinical information 
is also available thus making possible to draw relationships between gene expression 
patterns and clinical and prognostic features of cancer. Integrated bioinformatics 
approaches permit to identify tumour related signatures, molecular subtypes of 
cancer, and biomarkers. Relevant findings can then be further investigated in cellular 
models in order to define precise molecular mechanisms. 
In our laboratory we focus particularly on the study of serous ovarian cancer and 
breast cancer. During the first part of my doctorate I concentrated on the study of two 
genes: GTSE1 and HMGA1. Both genes (and their coded proteins) are well 
characterised from a molecular point of view but their role in cancer is still not clear. 
Using gene expression data coming from cancer patients, I tried to define the 
relevance of these genes for cancer related processes, for the prognosis of the disease 
and for their use as a molecular marker. 
HMGA1 expression in primary breast tumours 
The HMGA gene family plays important roles in proliferation, differentiation and 
stem cell self-renewal (Shah and Resar, 2012). Generally, the expression of HMGA 
genes is restricted to embryogenesis and, with few exceptions, is very low in normal 
adult cells (Sgarra et al., 2004). However, in transformed cells, HMGA genes are 
expressed at high levels, representing a possible feature of human malignancies. 
Several studies have reported that HMGA1 expression is high in a variety of human 
cancers, including carcinomas derived from prostate, colon and breast tissues (Fusco 
and Fedele, 2007). In recent years, studies have demonstrated a causal role of the 
HMGA1 protein in promoting a transformed phenotype (Berlingieri et al., 2002; 
Dolde et al., 2002; Liau et al., 2006; Reeves et al., 2001; Takaha et al., 2004; Wood et 
al., 2000) and the presence of the HMGA1 protein has been correlated with a higher 
grade in mammary epithelial cancer (Chiappetta et al., 2004; Ram et al., 1993). These 
results suggest that HMGA1 may be a key player in cancer related processes, in 
particular in breast cancer. It has already been shown that the HMGA1 gene is 
overexpressed in 60% of sporadic ductal carcinomas (Chiappetta et al., 2004), but it is 
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still unclear whether HMGA1 is enriched in a particular molecular subtype.  
To enlighten the importance of HMGA1 in breast cancer, I compared the abundance 
of HMGA1 mRNA with clinical variables such as tumour subtype and grade, which 
are important indicators of breast cancer prognosis (Perou et al., 2000; Sørlie et al., 
2001), by analysing a public primary breast cancer microarray meta-dataset (1881 
samples). The analysis revealed that HMGA1 mRNA levels are higher in the basal-
like and HER2+ subtypes respect to the luminal A, luminal B and normal-like 
subtypes (Figure 14A). I also found a strong association between HMGA1 expression 
and the absence of the oestrogen receptor (Figure 14B). In fact, both the basal-like 
and HER2+ subtypes are oestrogen receptor-negative breast cancer subtypes and, 
comparing directly tumours positive for the receptor against tumours negative for the 
receptor, the HMGA1 gene is significantly more expressed in the latter group. Finally, 
HMGA1 mRNA expression was associated with tumour grade (Figure 14C); tumours 
with a higher HMGA1 expression exhibit a higher grade. 
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Figure 14: HMGA1 expression in breast cancer. The level of expression of HMGA1 gene is shown across 
breast cancer subtypes (A), ER-status (B) and grades (C).  
 
The HMGA1 gene signature is an independent predictor of poor clinical outcome 
In order to understand the functional involvement of HMGA1 in breast cancer 
malignancy I investigated how HMGA1 alters the transcriptional program in breast 
cancer cell lines by analysing the transcriptional profile of breast cancer cells in the 
presence and absence of HMGA1. For this analysis a cellular model of an inducible 
cellular system for HMGA1 silencing based on siRNA in the oestrogen receptor-
negative basal-like human breast cancer cell line MDA-MB-231 was used.  
Performing unsupervised hierarchical clustering of gene expression data, I identified 
two gene cluster of genes differentially expressed after HMGA1 silencing (Figure 
15): the first cluster contains the genes that were most up-regulated (siHMGA1 UP 
A" B"
C"
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genes, n=38); the second cluster is larger and contains the genes that were most down-
regulated (siHMGA1 DW genes, n=130) (see Supporting Material Table S4 and S5) 
for complete lists of differential expressed genes). This finding is consistent with 
notion that HMGA1 acts predominantly as a transcription activator. The effects of 
HMGA1 depletion on the expression of selected genes were confirmed by qRT- PCR 
(see Supporting Material Figure S1). Functional annotation analysis of the genes 
regulated by HMGA1 silencing, performed with the DAVID/EASE and Ingenuity 
Pathway Analysis (IPA) tools, led to the conclusion that HMGA1 silencing affects 
genes involved in the regulation of the cell cycle, cellular movement, growth, 
proliferation, metabolism and cancer (Table 7). 
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Figure 15: Microarray analysis of MDA-MB-231 breast cancer cell after HMGA1 depletion. Using the 
Affymetrix microarray technology, I characterized the gene expression profiles of human MDA-MB-231 cell lines 
with HMGA1-depleted and control cells. The results of the cluster analysis for the genes obtained from differential 
genes analysis are shown. 
 
 
Table 7: Functional analysis of genes regulated by HMGA1. Starting from the genes that were expressed in the 
silenced HMGA1 cells that had greater than a 1.4 log-fold change or lower than a 1.4 log-fold change with respect 
to the control cells, I used the publicly accessible software DAVID/EASE and Ingenuity Pathway Analysis. The 
most over-represented terms (p<10-5) in the down- regulated gene cluster in the silenced HMGA1 cells were 
related to the mitotic cell cycle and mitosis (upper panel), while the up-regulated gene cluster was characterised by 
GO and was related to metabolism, movement and proliferation (lower panel). 
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In order to address the hypothesis that the transcriptional programme induced by 
HMGA1 is important for tumour aggressiveness, I investigated the expression of the 
HMGA1 gene signature in different cancer datasets using the Oncomine web tool 
(www.oncomine.org)(Rhodes and Chinnaiyan, 2004; Rhodes et al., 2007). 
Interestingly, the results of this analysis clearly revealed higher expression in tumour 
tissues respect to the normal tissue (ratio 89/6) of the genes that were down-regulated 
after HMGA1 silencing (i.e., genes induced by HMGA1). In particular, these genes 
are highly expressed also comparing bad vs. good clinical outcome (ratio 55/4), 
especially for breast cancer (ratio 31/0) (Figure 16). Therefore, to further evaluate this 
clinical correlation, I analysed several breast cancer microarray datasets, which 
collectively consisted of more than 2000 patients. A Kaplan-Meier survival analysis 
showed that the expression of these genes was significantly correlated with clinical 
outcome. In particular, patients expressing high levels of these genes displayed a 
shorter time to distant metastasis (TDM) (Figure 17A). In addition, a higher HMGA1 
gene signature expression was associated with basal-like subtype and high-grade (G3) 
breast cancers (Figure 17B and C). Notably, the signature was also correlated with 
HMGA1 mRNA expression (Figure 18) supporting the idea that HMGA1 is able to 
control this specific transcriptional program both in cancer cell lines and in vivo. 
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Figure 16: Oncomine analysis. Starting with the genes expressed in the silenced HMGA1 cells that displayed less 
than a 1.4 log-fold change with respect to the control cells (HMGA1 signature), I used the Oncomine web tool to 
determine if there were any associations between the gene expression profiles of the different cancer types present 
in the database. This table displays the number of significant results, coloured red or blue for over- or under-
expression, respectively, across all cancer types, with an analysis of the correlation with clinical outcomes. P-
values were calculated using a two-sample paired Wilcoxon test. 
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Figure 17: HMGA1 signature in breast cancer. (A) Kaplan–Meier survival curve of time to distant metastasis 
(TDM) for breast cancer patients who were classified according to HMGA1 expression. Red line: cases with high 
HMGA1 expression; blue line: cases with low HMGA1 expression. (B-C) Boxplots of the distribution of the gene 
expression intensities of the HMGA1 gene signature across different breast cancer subtypes (intrinsic subtypes or 
Grades 1, 2 or 3).
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Figure 18: Correlation between HMGA1 and HMGA1-gene signature expression. We classified all of the 
breast cancer samples using the expressions of HMGA1 or corresponding signature obtained by our microarray 
experiments to evaluate their association. The mosaic plot shows the proportion of the four possible groups along 
with the number of samples in each group. Statistical analysis (using the Pearson's Chi-squared test) showed a 
significant correlation (p< 2.2e-16). 
 
I then assessed whether this signature could be an independent predictor of clinical 
outcome. Cox multivariate analysis revealed that the HMGA1 gene signature behaves 
as a significant (p<0.05) independent prognostic factor (Table 8). Then I repeated the 
analysis in a cohort of 115 patients in which many clinical variables were available. 
Also in this case I confirmed that the HMGA1 signature yields prognostic information 
(Table 9). Hence, the combined expression of the genes up-regulated by HMGA1 has 
prognostic significance and may be considered as a marker of breast cancer 
malignancy.  
 
Table 8: Multivariate analysis of risk of death. 
n=#586#
n=#115#
Figure'Supplementary'3:''Mul3variate'analysis'
'
A#
B#
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Table 9: Multivariate analysis of risk of death. 
 
HMGA1 final remarks 
The bioinformatics analysis was integrated with biological experiments in order to 
demonstrate that HMGA1 plays a pivotal role in regulating invasive processes and 
determining poor prognostic outcomes in breast cancer by sustaining the 
mesenchymal phenotype and stemness. Taken together, these data suggest that 
HMGA1 plays a key role in breast cancer malignancy and the progression of 
metastatic disease acting as an activator of a specific gene network. All results have 
already been published (Pegoraro et al., 2013). 
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GTSE1 Expression in Breast Cancers Correlates with Time to Metastasis, 
Invasiveness and Clinical Outcome 
The protein GTSE1 (G-2 and S-phase expressed 1) is a negative regulator of p53 that 
can shuttle between the cytoplasm and nucleus. After DNA damage, GTSE1 
accumulates in the nucleus, where it interacts with p53 and shuttles it out of the 
nucleus to promote its down-regulation and recovery from the p53-induced G2 DNA 
damage checkpoint (Liu et al., 2010; Monte et al., 2003, 2004). In the absence of 
DNA damage, GTSE1 localizes to interphase microtubules networks (Collavin et al., 
2000; Monte et al., 2000), and has also been found associated with clathrin-containing 
complexes (Borner et al., 2012; Hubner et al., 2010). Interestingly GTSE1 resulted 
regulated by HMGA1 and, in our laboratory, it has already been observed that GTSE1 
is overexpressed in several transformed cell lines with respect to non-transformed cell 
lines (see Supporting Material Figure S2): these observations led to the hypothesis 
that GTSE1 could act as an effector, performing specific molecular cancer-related 
functions regulated by HMGA1 transcriptional program. 
 
In order to identify potential clinical or cancer-related correlations with GTSE1 
expression, I looked for associations with any type of tumour using the Oncomine 
cancer microarray database (www.oncomine.org) (Rhodes et al., 2007) (Figure 19). 
This analysis identified 61 unique datasets where GTSE1 had significantly higher 
expression in tumour tissues as compared to normal tissues. Notably, worse clinical 
outcome was associated with increased GTSE1 expression in 12 cases, 10 of which 
were in breast cancer. 
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Figure 19: Oncomine analysis for GTSE1 Disease Summary: this view displays the number of significant results 
colored in red or blue for over- or under-expression, respectively, across all cancer types and analysis types in 
Oncomine. 
I then analysed several microarray data sets of breast cancer, collectively consisting of 
more than 2000 patients in order to delve deeper into clinical correlations with 
GTSE1 expression. Kaplan-Meier survival analysis of the combined data sets showed 
that breast cancer patients expressing higher GTSE1 levels in tumours displayed 
shorter time to distant metastasis (p<10-15; Figure 20A). Notably, the correlation 
between GTSE1 expression and the grade of breast cancers is significant, with the 
most invasive and aggressive cancers (Grade 3) showing highest expression of 
GTSE1 (Figure 20B). Taking all together, these data show a correlation between the 
deregulation and overexpression of GTSE1 and tumour invasiveness and cancer 
prognosis. 
Disease Summary for GTSE1 
 
Threshold (Gene Rank): Top 10% Threshold (Fold Change) 1.5 Threshold (P-value): 0.001 Data Type: All 
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Figure 20: GTSE1 expression in breast cancer tumours and cells correlates with time to metastasis and 
invasiveness. (A) Kaplan–Meier survival curve of time to distant metastasis of breast cancer patients classified 
according to the expression of GTSE1. Red line: cases with high expression of GTSE1, blue line: cases with low 
expression of GTSE1. (p<10–15) (B) Boxplots of the distribution of gene expression intensities of GTSE1 across 
different breast cancer subtypes (Grade 1, 2 or 3; p<10-5; linear regression analysis). 
 
GTSE1 final remarks 
In order to delve deeper the functional role of GTSE1, in our laboratory we performed 
gene expression profiling silencing GTSE1 in TNBC-cell lines. Functional analysis 
confirmed that the perturbed functions include cell adhesion, cell junction and 
endocytosis biological themes. This analysis also led to the selection of potential 
molecules that can target specific genes modulated by GTSE1 silencing.  
The bioinformatics analysis was integrated with biological experiments demonstrating 
that the molecular activity of GTSE1 leading to stimulation of cell migration and loss 
of focal adhesions is EB1-dependent microtubule plus-end tracking, providing an 
intriguing link between microtubule plus-end functions and metastasis. All results 
have been published (Scolz et al., 2012). 
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DISCUSSION 
 
Nowadays, different cancer gene expression datasets are publically available and can 
be interrogated with the aim of generating new biological hypothesis or validating the 
existing ones. Usually genes are characterized as onco-genes or onco-supressors. Such 
definitions are restricting and do not give information about how the gene performs its 
pro- or anti- tumour activity. Even through the mechanisms and pathways exploited 
by cancer cells in order to elude apoptosis and cell cycle control are the same, each 
tumour subtype relies on a different set of alterations. Because of this, often, gene 
signatures have clinical relevance only in some tumour types or subtypes but not in 
others.  In the case of HMGA1, it is known that the HMGA gene family plays 
important roles in proliferation, differentiation and stem cell self-renewal and that in 
transformed cells, HMGA genes are expressed at high levels, thus indicating a 
possible role in cancer. Using bioinformatics approaches I demonstrated that HMGA1 
is highly expressed in breast cancers with poor prognosis and with the tendency to 
metastasize. Interestingly, the HMGA1 signature overlaps with other signatures that 
identify patients with poor prognosis; in fact, some genes in the signature (CENPF, 
CENPA, CCNE2, BUB1 and PSMD2) are part of the 70-gene prognosis profile (van  
’t Veer et al., 2002) and Pin1/mutant p53 signature(Girardini et al., 2011). 
The microarray analysis indicates that HMGA1 is able to regulate genes implicated in 
microtubules dynamics, and among them, GTSE1 has emerged as a microtubule-
associated protein. My bioinformatics analyses indicate both GTSE1 and HMGA1 as 
genes implicated in cancer related processes and having relevance for prognosis; the 
former acting as regulator of a general transcription program, the latter as effector 
performing specific molecular functions. 
Importantly, the molecular activity of GTSE1 leading to stimulation of cell migration 
and loss of focal adhesions is EB1-dependent microtubule plus-end tracking: this 
result provides an intriguing link between microtubule plus-end functions and 
metastasis. We can suppose that this mechanism is not specific of breast cancer, but 
shared between cancer types with tendency to metastasize. In fact, upregulation of 
GTSE1 expression was identified as a potential marker for metastasis in oral tongue 
squamous cell carcinoma (Zhou et al., 2006) and more recently, GTSE1 was 
identified as one of three cell cycle regulatory genes (along with CDKN3 and Cyclin 
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B1) whose upregulation in gastro-enteropancreatic neuroendocrine tumours correlate 
with metastasis (Lee et al., 2012). These results are consistent with the observation 
that GTSE1 mRNA expression levels correlate with time to metastasis and tumour 
grade in breast cancer.  
The question regarding how HMGA1 can regulate GTSE1 is still unresolved, but we 
are actually collecting multiple evidences that GTSE1 is regulated by TEAD, a 
component in the Hippo pathway, playing essential roles in mediating biological 
functions of YAP (Zhao et al., 2008). Intriguingly, HMGA1 is able to regulate YAP 
localization (Pegoraro et al., in preparation) thus permitting to hypothesize a novel 
axis capable of modulate breast cancer aggressiveness. The Integration of different 
bioinformatics and molecular approaches lead to the characterization of this axis, 
identifying HMGA1 as the main regulator of a complex transcriptional program and 
GTSE1 as one of the down-stream effectors. 
 
Even though cancer tissues gene expression profiles are widely used to define genes 
signatures and test their clinical relevance, they do not take into account to the fact 
that tumours are composed by heterogeneous tissue; cancer cells interact with the 
cancer microenvironment in order to orchestrate tumour growth, drug resistance and 
metastasis. Focusing on the cancer supporting cell compartment could enlighten 
specific molecular mechanisms and biomarkers, also relevant for prognosis and 
clinical outcome; actually, the dissection and characterization of the distinct cellular 
lineages and their respective progenitors giving rise to the various cell types that form 
the tumour-tissue could be addressed only through in vitro models.  
One of the cellular lineages that compose both normal and cancer tissue 
microenvironments are Mesenchymal Stem/Stromal Cells (MSCs). In our laboratory, 
MSCs from High-Grade Serous Ovarian Cancers (HG-SOCs) and various normal 
tissues (N-MSCs) have been isolated and their transcriptional activity have been 
analysed with respect to the large comprehensive FANTOM5 sample dataset. 
 
The FANTOM5 project used single molecule CAGE sequencing to generate a 
promoter-level expression atlas displaying the transcriptional regulatory networks that 
define the majority of mammalian cells and tissues.  
Taking advantage of the deep-CAGE-seq data it has been possible to show that HG-
SOC-MSCs possess distinct and specific CAGE-peak promoter activities with respect 
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to N-MSCs. Moreover, looking at the distribution of all CAGE-peaks across the entire 
gene length, the differential analysis suggested the possible existence of a specific 
epigenetic-based mechanism explaining such global CAGE-peak patterns. Altogether, 
the highlighted shared functional programs between HG-SOC-MSCs and N-MSCs 
suggest that the global differences are based on quantitative levels of transcriptional 
output rather than on qualitative differences in the expressed genes. Taking into 
account the fact that HG-SOC-MSCs are not transformed cells, this results enlighten a 
particular plasticity of MSCs from a transcriptional point of view, possibly in 
response to external stimuli coming from tumour microenvironment. The existence of 
specific identities in MSCs has been recently described in murine MSC-like cells 
derived from different tissues (bone-marrow, heart and kidney)(Pelekanos et al., 
2012). It has been observed that bone marrow-derived MSC-like cells cannot replace 
MSC-like cells of pro-epicardial origin in myocardial infarction (Chong et al., 2011) 
and MSCs originating from different sources show a different healing performance in 
cardiac regeneration (Gaebel et al., 2011), so such specific heterogeneity seems to be 
critical at the functional level.  
Both differential gene expression and differential gene peak usage analysis results 
suggested that HG-SOC-MSCs are close relatives of mesothelial cells, smooth muscle 
cells and fibroblasts. This result could be related to the district of origin of these cells. 
It has been recently shown (Rinkevich et al., 2012b) that the mesothelium derived 
from various adult mouse organs contains the precursors of Fibroblasts and Smooth 
Muscle Cells (FSMCs). A possible hypothesis is that HG-SOC-MSCs could derive 
from the ovarian mesothelium or other local mesothelia. Similarly, all the 
accumulated evidences (Auersperg, 2013; Berek et al., 2012; Karst et al., 2011; Kim 
et al., 2012; Levanon et al., 2008) support the mesothelia of ovarian surface 
epithelium (OSE) and fallopian tube fimbriae as the site of origin of the cancer cell 
compartment of high-grade serous ovarian, peritoneal, and fallopian tube cancers. An 
alternative to the above-proposed hypothesis, the HG-SOC microenvironment could 
instruct, via epigenetic mechanisms, the conditioning of recruited bone marrow MSCs 
to acquire the overall mesothelial signatures common to their specific origin. Future 
transcriptomics analysis of mesothelial-derived cells obtained from different tissue 
districts will uncover their complex biology and heterogeneity, shedding light on the 
potential role they might play in the microenvironment of HG-SOC and other 
aggressive tumours.  
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Noticeably we found CAGE-peak differences also between the various normal tissue-
derived MSCs: heart-derived MSCs showed a similar overall mesothelial signature as 
found in HG-SOC-MSCs with respect to adipose and bone marrow-derived N-MSCs. 
In order to address a potential role of HG-SOC-MSCs in serous ovarian cancer, I 
derived a gene signature composed of nine genes. These genes consist of five 
established mesothelial markers and four mesothelial-related genes. This signature 
showed a statistically significant correlation with bad prognosis when used to 
interrogate a large SOC meta-dataset. Given that its performance was either 
statistically non-significant in the case of lung cancer or correlated with good 
prognosis in the case of breast cancer we can hypothesise that such correlation is 
specific for HG-SOC. This observation supports the hypothesis that high-grade serous 
ovarian cancer derives from mesothelium of ovarian surface epithelium (OSE) and 
fallopian tube fimbriae. 
 
For the characterization of HG-SOC-MSCs it had been essential the use of the 
FANTOM5 dataset: in fact, one of the main features of the dataset is that it includes 
samples coming from human tissues, primary cell lines and transformed cell lines thus 
allowing the comparison of the cell lines of interest, not only respect to all the other 
cell lines, but also respect to the tissues of the human body. Furthermore, since the 
FANTOM5 dataset is focused on promoter utilization, it represents an excellent 
source of information for the study of gene expression regulation mechanisms.  
I and my group wondered if the identification of enriched composite elements in the 
genomic regions surrounding FANTOM5 CAGE peaks could enhance the ability to 
understand the regulatory networks in different tissues.  
Our new software, ScanAll, tries to get rid of the limits associated with phylogenetic 
and statistical approaches (Simcha et al., 2012) (such as computational time, input 
sequences size limitations, and use of inappropriate background), some of which 
depending on the fact of relying on existing knowledge. 
In fact, available collections of transcription factor binding sites account for some 
hundreds of non-redundant profiles, with respect to an estimated number of ~1700 
different human TFs (Vaquerizas et al., 2009; Wingender et al., 2013). A single DNA-
binding domain shared by multiple TFs could allow the interaction of several proteins 
to very similar DNA sequences; however, splicing variants of a single TF could have 
very different binding specificities (Giguère et al., 1995). It is hence likely that 
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existing catalogues of binding profiles provide an underrepresentation of the total 
number of binding sites in the genome.  
Nowadays, an increasing number of high quality binding site profiles are added on a 
regular basis to TFBS collections. However, methods based on PWMs lead to the risk 
of underestimating the importance of less studied transcription factors (Pavesi et al., 
2004; Sandve et al., 2007; Tompa et al., 2005). Moreover, even for methods not using 
PWMs, the risk of inaccurate predictions (Pavesi et al., 2004) is high when the 
significance of an analysis involves motif frequencies calculated by only taking into 
account known regulatory regions, as a background. Finally, there are methods that 
only predict a single enriched motif per set of sequences (Pavesi et al., 2004; Sandve 
et al., 2007; Tompa et al., 2005), that account for up to one single occurrence of any 
enriched motif per sequence, or that do not permit to analyse subsets of the input 
datasets. 
The possibility provided by ScanAll to look for structured enriched modules, instead 
of single motifs, permits to getting rid of the aforementioned restrictions. The 
introduction of a dedicated filtering pipeline based on the comparison of our results 
against random sequences greatly reduced the number of false positive results.  
The choice of motif length ℓ (set to six) reflected the average length of the conserved 
TFBS core sequences; in combination with the number of mismatches d (set to one) 
they constitute one of the motif layouts commonly searched by existing methods 
(Narasimhan et al., 2003; Pavesi et al., 2007). By looking at the promoter coverage 
obtained by mapping the module-composing enriched elements, we could find that 
instead of providing a completely random painting of the analysed region, they 
specifically localized at precise spots, thus confirming the topological specificity of 
our findings in identifying binding regions. These results are obtained by introducing 
two concepts: the notion of complexity and that of quorum. Complexity is the number 
of different nucleotides required to appear in every motif and it was fixed to four in 
order to maximize the structural diversity of enriched sequences (and hence the 
probability to identify biologically relevant elements). The choice of quorum during 
motifs discovery was arranged in order to correspond (on average) to 10% of the 
estimated number of genomic sequences (i.e. active promoters) in each FANTOM5 
sample. The values we used for these parameters, although not arbitrary, could 
sometimes lead to evident drawbacks, like the loss of known TFBS with simple 
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structures (i.e. sites for SP1, SP3, NHLH or ZFX) or the absence of seldom-
represented modules occurring only in very few promoters. 
Spacing between motifs forming CRMs varies depending on the involved TFs and on 
the face of the DNA double helix where the interactions occur. Recent evidence 
suggest that the lower bound is generally between 25 and 50 nucleotides (Huang et 
al., 2012), a value frequently used also by composite motifs discovery methods (Frith 
et al., 2001, 2003; Kel et al., 2006; Zhou and Wong, 2004). Conversely, the upper 
bound still preserving the possibility for two closely positioned TFs to interact 
synergistically is estimated to be around 100 nucleotides (Courey, 2008; Girgis and 
Ovcharenko, 2012). For these reasons, we set our pipeline to discover enriched 
modules made of motifs separated by 40-90 nucleotides. We wanted them to be close 
enough to ensure co-binding between putative interacting TFs, while also allowing a 
sufficient interval enabling the combinations of TFBS for regulatory proteins not 
directly interacting with each other, as happening in large transcriptional complexes. 
All these parameters were chosen based on specific considerations, but they are 
however all completely user-definable and can hence be adapted to different 
analytical conditions. 
In order to get a broader representation of the full biological potential of these 
modules, we evaluated 1) the expression status of all the TFs that putatively bound the 
discovered enriched elements and 2) their ability to establish direct protein-protein 
interactions (PPI). This led us to the creation of the “Expressed module 
Compendium” and “PPI Expressed Compendium”. These collections allowed us to 
have direct evidence of the sample-specific switches taking place between the 
expressed TFs: depending on the cellular context, in fact, they selectively associated 
with different binding partners. 
Based on these results, our Compendium represents a useful source of information in 
order to associate the presence of enriched composite regulatory modules, the 
expression of TFs to human tissues and known direct protein interactions between 
TFs to specific human tissues.  
This information could be of particular relevance is cancer, which has been described 
as a disease of disrupted gene regulation: it is therefore unsurprising that non-coding 
variations are linked to tumorigenesis. A possible challenge is to predict whether the 
alteration in a specific cis-regulatory element is likely to have a functional 
consequence. Existing predictive approaches can involve multiple lines of evidence: 
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TF–DNA interactions arise from the interplay between DNA sequence motifs, 
chromatin accessibility, epigenetic marks, and interactions with cofactors. In order to 
prioritize functional regulatory elements, multiple aspects of TF–DNA interactions 
have to be taken into account and the integration of different types of information is 
needed (Mathelier et al., 2015). 
This integrative approach makes also feasible the perspective of creating tissue 
specific regulatory networks and analyse them in order to find specific or shared 
regulatory circuits. Recently, network analysis has been proposed in drug discovery 
studies (Huang et al., 2014; Ryall and Tan, 2015; Tang et al., 2013) where, because of 
the failure of single targets to successfully translate into clinical practice and the 
problem of development of drug resistance with single target cancer therapies, the 
interest in discovery of effective drug combinations has increased. The combination 
therapies may dramatically improve efficacy of cancer therapies and systems biology 
approaches are needed to prioritize combinations for experimental testing. 
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Table S1: Clinical-pathological characteristics of the patients considered in the study. Characteristics of each 
tumor sample from which HG-SOC-MSCs used in cell-based assays were isolated.  
SAMPLE AGE  DIAGNOSIS MITOSIS (SCORE) 
GRADING 
(S) pTNM  FIGO ST 
sample 12 56 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
79/10HPF(3) 3 (8) pT3b,Nx,Mx IIIB 
sample 17 75 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
48/10HPF 
(3) 3 (8) pT3c,Nx,Mx IIIC 
sample 19 47 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
46/10HPF 
(3) 3 (9) pT3c,Nx,Mx IIIC 
sample 26 64 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
37/10HPF 
(3) 3 (8) pT3c,Nx,Mx IIIC 
sample 31 23 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
17/10HPF 
(2) 2(6) pT3c,N1,M1(cute) IV 
sample 33 70 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
46/10HPF 
(3) 3 (9) pT3c,Nx,Mx IIIC 
sample 34 51 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
60/10HPF 
(3) 3 (9)     
sample 36 52 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
48/10HPF 
(3) 3 (9) pT2c,Nx,Mx IIC 
sample 38 68 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
68/10HPF 
(3) 3 (9) pT3c,N0,Mx IIIC 
sample 39 30 BORDER SEROUS ADENOCARCINOMA  0/10HPF(1) 1(5) pT1C,N0,Mx IC 
sample 40 55 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
28/10HPF 
(3) 3 (9) pT2b,Nx,Mx IIB 
sample 41 39 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
66/10HPF 
(3) 3 (9)     
sample 43 83 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
50/10HPF 
(3) 3 (9) pT3b,Nx,Mx IIIB 
sample 48 47 BORDER SEROUS ADENOCARCINOMA  
12/10HPF 
(2) 2(6) pT1A,N0,Mx IA 
sample 49 56 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
166/10HPF 
(3) 3 (8) pT3a,Nx,Mx IIIA 
sample 57 63 
HIGH-GRADE 
SEROUS 
ADENOCARCINOMA  
36/10HPF 
(3) 3 (9) pT3c,Nx,Mx IIIc 
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Table S2 
! ! !
! INJECTED!MICE!(n)! TUMOURS!(n)!
HG$SOC$MSCs!(19$02)! 2! 0!
HG$SOC$MSCs!(41$01)! 2! 0!
HG$SOC$MSCs!(43$01)! 2! 0!
TOT! 6! 0!
! ! !
! INJECTED!MICE!(n)! TUMOURS!(n)!
SKOV63! 5! 5!
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Table!S3!A!
! !
GENE!SYMBOL! P.VALUES! DIFFERENTIAL!GLOBAL!PEAK!VALUE!(HG6SOC6MSCs_vs_N6MSCs)!
SERPINE1! 0.032597848! 4.24!
ERO1L! 1.86E$05! 2.22!
RAC2! 8.54E$06! 1.80!
GNG11! 0.01561648! 1.73!
ITGB1! 0.014141219! 1.67!
F2RL1! 0.000630888! 1.63!
FRMD4A! 0.000415651! 1.51!
SULF1! 0.040224159! 1.51!
MIR663B! 0.020494662! 1.46!
TRIO! 0.027126448! 1.41!
KPNA4! 0.000745618! 1.30!
DCBLD2! 0.018337521! 1.23!
DPYSL3! 0.036048586! 1.22!
UBE2D3! 0.005904836! 1.20!
ITGA3! 0.000456793! 1.18!
ANTXR2! 0.000708471! 1.14!
HMGA2! 0.026622099! 1.13!
C1QTNF1! 0.033070151! 1.11!
EZR! 0.008053422! 1.09!
MAP2K1! 0.001698256! 1.09!
NF1! 0.002856186! 1.08!
LRRFIP1! 0.004071572! 1.07!
ECE1! 0.021515579! 1.04!
CORO2B! 0.044379945! 1.01!
MYADM! 0.001833474! 1.01!
SPON2! 0.038437698! 1.01!
DKK3! 0.00846815! 1.00!
CD82! 0.012641189! 0.99!
PGAM1! 0.012641189! 0.99!
STC1! 0.002154894! 0.99!
ACTN1! 0.001163193! 0.98!
SEMA3C! 0.017761272! 0.98!
ITGA2! 0.013781792! 0.97!
PGK1! 0.013609481! 0.97!
IL33! 0.005434391! 0.96!
HUWE1! 0.028007808! 0.96!
PLS3! 0.006032561! 0.94!
FNDC3A! 0.005058224! 0.91!
SGK1! 0.020603751! 0.91!
BNIP3! 0.000198602! 0.89!
PHLDB1! 0.000202043! 0.88!
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FAM177A1! 0.012631333! 0.87!
TNIP1! 0.009971161! 0.86!
ABLIM3! 0.008416762! 0.84!
BAZ2A! 0.011638538! 0.84!
ANTXR1! 0.04870766! 0.80!
CDV3! 0.017432394! 0.79!
INHBA! 0.020159711! 0.79!
SPTBN1! 0.009496772! 0.79!
CREB3! 0.001725101! 0.78!
HDAC1! 0.031940382! 0.77!
NBEAL1! 0.031940382! 0.77!
PDLIM4! 0.006101891! 0.77!
ZMAT3! 0.031940382! 0.77!
CDCP1! 0.044024973! 0.74!
CTPS! 0.005479976! 0.74!
LACTB! 0.034427427! 0.74!
SH3BP4! 0.005479976! 0.74!
TMEM45A! 0.004733273! 0.72!
YWHAG! 0.036916396! 0.71!
DYNLT3! 0.001322951! 0.70!
FGFR1OP2! 0.009534613! 0.70!
VMP1! 0.025909045! 0.70!
CTNNB1! 0.001016734! 0.69!
YAP1! 0.027023452! 0.64!
NUTF2! 0.012450834! 0.63!
FAR1! 0.011519521! 0.62!
STT3B! 0.007912131! 0.61!
RALA! 0.005121073! 0.60!
TRIP12! 0.005121073! 0.60!
ACTA2! 0.006628844! 0.59!
ARPC5! 0.006628844! 0.59!
TMEM123! 0.009907153! 0.58!
TOR1AIP1! 0.009907153! 0.58!
TSPAN9! 0.0493146! 0.57!
CASK! 0.013349063! 0.56!
OSBPL9! 0.013349063! 0.56!
RNF181! 0.013349063! 0.56!
SUN2! 0.013349063! 0.56!
ASAP1! 0.023910764! 0.53!
PLXNB2! 0.014956364! 0.50!
SERPINB6! 0.048949735! 0.50!
RHOA! 0.037702915! 0.48!
CAPNS1! 0.044214858! 0.47!
VDAC1! 0.044214858! 0.47!
GBE1! 0.042385344! 0.46!
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TCEB1! 0.043653925! 0.43!
ARHGAP18! 0.043653925! 0.43!
H6PD! 0.048680346! 0.42!
STK17B! 0.048680346! 0.42!
TAF9! 0.044839993! 0.41!
ARFIP1! 0.036787498! 0.40!
ATP1A1! 0.036787498! 0.40!
C9orf25! 0.036787498! 0.40!
CHMP7! 0.036787498! 0.40!
COX19! 0.036787498! 0.40!
CPPED1! 0.036787498! 0.40!
EPT1! 0.036787498! 0.40!
F3! 0.036787498! 0.40!
GOLIM4! 0.036787498! 0.40!
GPATCH2! 0.036787498! 0.40!
GPR180! 0.036787498! 0.40!
GYS1! 0.036787498! 0.40!
ICAM1! 0.036787498! 0.40!
IDE! 0.036787498! 0.40!
IFNAR2! 0.036787498! 0.40!
JMJD1C! 0.036787498! 0.40!
KCTD20! 0.036787498! 0.40!
MACF1! 0.036787498! 0.40!
MLLT11! 0.036787498! 0.40!
OSGIN2! 0.036787498! 0.40!
PLD3! 0.036787498! 0.40!
PPFIA1! 0.036787498! 0.40!
RBM6! 0.036787498! 0.40!
TBX3! 0.036787498! 0.40!
TERF2IP! 0.036787498! 0.40!
TES! 0.036787498! 0.40!
TNFAIP3! 0.036787498! 0.40!
TP53RK! 0.036787498! 0.40!
VGLL4! 0.036787498! 0.40!
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Table!S3!B!
! !
GENE!SYMBOL! P.VALUES! DIFFERENTIAL!GLOBAL!PEAK!VALUE!(HG6SOC6MSCs_vs_N6MSCs)!
FN1! 0.029767291! $26.12!
COL1A2! 2.65E$02! $2.77!
MFAP5! 1.18E$02! $2.27!
COL6A1! 0.038126203! $2.21!
ISLR! 0.00318969! $2.09!
CCDC80! 0.027140069! $1.94!
PRRX1! 0.006529897! $1.69!
DCN! 0.001511675! $1.67!
PMP22! 0.001823658! $1.63!
PCOLCE! 0.003538774! $1.26!
PDGFRB! 0.037153657! $1.21!
TMEM43! 0.03742545! $1.19!
MYOF! 0.014424954! $1.14!
EIF6! 0.001108348! $1.13!
ANGPTL2! 0.008413587! $1.12!
PTRF! 0.013349063! $1.11!
41526! 0.032150582! $1.08!
HSPB6! 0.005320076! $1.06!
AKT1S1! 0.007972306! $1.03!
PDE4DIP! 0.046313095! $0.98!
BRP44L! 0.000937456! $0.93!
RPL34! 0.001961531! $0.91!
ACAA2! 0.014774056! $0.90!
SH3D19! 0.00044674! $0.90!
NME4! 0.006210589! $0.88!
NFIX! 0.021786337! $0.87!
IL1R1! 0.008416762! $0.84!
CD248! 0.032156376! $0.83!
CTSA! 0.020217864! $0.83!
BAG2! 0.028149726! $0.80!
JTB! 0.000202499! $0.80!
NFIC! 0.009396685! $0.79!
MRPS33! 0.021259985! $0.74!
FAM125A! 0.036916396! $0.71!
EFEMP1! 0.001016734! $0.69!
TGFBR2! 0.00939512! $0.69!
EMP3! 0.001820564! $0.68!
IFI16! 0.009663676! $0.68!
MLF2! 0.003949773! $0.67!
PDGFRA! 0.039080981! $0.66!
C16orf45! 0.032271821! $0.63!
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SERTAD2! 0.039335268! $0.62!
LOXL1! 0.023856385! $0.60!
MYO1B! 0.005121073! $0.60!
TXNDC5! 0.006628844! $0.59!
UGP2! 0.006628844! $0.59!
C6orf72! 0.009907153! $0.58!
GLT8D1! 0.043653925! $0.58!
TGFB1! 0.009907153! $0.58!
GCLM! 0.014956364! $0.50!
LTA4H! 0.014956364! $0.50!
CNBP! 0.025277358! $0.49!
PLIN3! 0.025277358! $0.49!
RPL39! 0.025277358! $0.49!
HNRNPUL1! 0.037702915! $0.48!
PCBP1! 0.037702915! $0.48!
FKBP1A! 0.042385344! $0.46!
NDUFAF3! 0.042385344! $0.46!
VAV3! 0.042385344! $0.46!
ALAS1! 0.035265203! $0.44!
ALG10! 0.035265203! $0.44!
C6orf108! 0.035265203! $0.44!
CCDC12! 0.035265203! $0.44!
DGCR6L! 0.035265203! $0.44!
FAM165B! 0.035265203! $0.44!
GPR108! 0.035265203! $0.44!
METRNL! 0.035265203! $0.44!
NADK! 0.035265203! $0.44!
RNF24! 0.035265203! $0.44!
SIGIRR! 0.035265203! $0.44!
SLFN11! 0.035265203! $0.44!
TBC1D5! 0.035265203! $0.44!
TERC! 0.035265203! $0.44!
CYBRD1! 0.035265203! $0.44!
JAGN1! 0.043653925! $0.43!
AK1! 0.048680346! $0.42!
PAMR1! 0.048680346! $0.42!
ACOT13! 0.044839993! $0.41!
ACAT1! 0.036787498! $0.40!
ARL26SNX15! 0.036787498! $0.40!
FKBP9! 0.036787498! $0.40!
PHLDA3! 0.036787498! $0.40!
PRUNE2! 0.036787498! $0.40!
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Table S4 
Genes up-regulated after HMGA1 silencing 
SymbolID_coef1 ID logFC P.Value adj.P.Val 
ERBB4! 214053_at! 2.38! 1.06E$08! 9.92E$07!
NAALAD2! 1554507_at! 2.04! 1.08E$07! 4.31E$06!
PTGS1! 238669_at! 1.98! 1.64E$07! 5.85E$06!
CAPN8! 229030_at! 1.94! 2.06E$07! 6.68E$06!
LGR5! 213880_at! 1.90! 1.72E$08! 1.29E$06!
COL3A1! 215076_s_at! 1.87! 1.91E$10! 1.09E$07!
SH2D3A! 219513_s_at! 1.84! 8.35E$10! 2.17E$07!
FABP4! 203980_at! 1.81! 1.03E$09! 2.39E$07!
TMEM156! 241844_x_at! 1.81! 5.72E$10! 1.91E$07!
DNAH12! 243802_at! 1.76! 1.15E$10! 8.68E$08!
BCCIP! 227896_at! 1.74! 1.99E$10! 1.09E$07!
GDPD1! 238681_at! 1.70! 1.36E$08! 1.15E$06!
KBTBD8! 239835_at! 1.68! 1.16E$09! 2.56E$07!
DPYD! 1554536_at! 1.67! 4.23E$10! 1.55E$07!
ABCG2! 209735_at! 1.66! 1.38E$11! 3.91E$08!
GKN2! 238222_at! 1.64! 1.01E$08! 9.66E$07!
AGXT2L1! 221008_s_at! 1.62! 1.32E$07! 4.95E$06!
AKR1B10! 206561_s_at! 1.60! 1.09E$09! 2.48E$07!
PFKFB2! 209992_at! 1.58! 4.55E$09! 6.01E$07!
C9orf95! 219147_s_at! 1.56! 5.19E$08! 2.66E$06!
LOC100505989! 238103_at! 1.55! 1.28E$09! 2.64E$07!
CHMP4C! 226803_at! 1.53! 6.88E$09! 7.61E$07!
TXNRD3! 59631_at! 1.53! 4.21E$08! 2.31E$06!
CBLB! 227900_at! 1.50! 1.68E$09! 3.19E$07!
MAP7! 202890_at! 1.49! 4.41E$08! 2.38E$06!
SAMD5! 228653_at! 1.49! 7.42E$09! 7.94E$07!
MAL2! 224650_at! 1.48! 3.85E$08! 2.19E$06!
RELN! 205923_at! 1.47! 2.65E$08! 1.67E$06!
FAT3! 236029_at! 1.46! 6.49E$10! 1.97E$07!
PGAP1! 244321_at! 1.45! 1.38E$08! 1.15E$06!
ESRP2! 229223_at! 1.44! 2.03E$07! 6.61E$06!
PPM1H! 212686_at! 1.42! 3.95E$09! 5.48E$07!
FAM83H! 226129_at! 1.42! 2.44E$10! 1.14E$07!
LOC100506713! 229833_at! 1.42! 5.82E$09! 6.77E$07!
PCDH7! 205535_s_at! 1.40! 2.87E$09! 4.51E$07!
ST20! 217104_at! 1.40! 2.41E$07! 7.51E$06!
TMEM45A! 219410_at! 1.40! 4.33E$08! 2.35E$06!
PPP2R1B! 222351_at! 1.40! 2.16E$09! 3.79E$07!
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Table S5 
Genes up-regulated after HMGA1 silencing 
SymbolID_coef1 ID logFC P.Value adj.P.Val 
ERBB4! 214053_at! 2.38! 1.06E$08! 9.92E$07!
NAALAD2! 1554507_at! 2.04! 1.08E$07! 4.31E$06!
PTGS1! 238669_at! 1.98! 1.64E$07! 5.85E$06!
CAPN8! 229030_at! 1.94! 2.06E$07! 6.68E$06!
LGR5! 213880_at! 1.90! 1.72E$08! 1.29E$06!
COL3A1! 215076_s_at! 1.87! 1.91E$10! 1.09E$07!
SH2D3A! 219513_s_at! 1.84! 8.35E$10! 2.17E$07!
FABP4! 203980_at! 1.81! 1.03E$09! 2.39E$07!
TMEM156! 241844_x_at! 1.81! 5.72E$10! 1.91E$07!
DNAH12! 243802_at! 1.76! 1.15E$10! 8.68E$08!
BCCIP! 227896_at! 1.74! 1.99E$10! 1.09E$07!
GDPD1! 238681_at! 1.70! 1.36E$08! 1.15E$06!
KBTBD8! 239835_at! 1.68! 1.16E$09! 2.56E$07!
DPYD! 1554536_at! 1.67! 4.23E$10! 1.55E$07!
ABCG2! 209735_at! 1.66! 1.38E$11! 3.91E$08!
GKN2! 238222_at! 1.64! 1.01E$08! 9.66E$07!
AGXT2L1! 221008_s_at! 1.62! 1.32E$07! 4.95E$06!
AKR1B10! 206561_s_at! 1.60! 1.09E$09! 2.48E$07!
PFKFB2! 209992_at! 1.58! 4.55E$09! 6.01E$07!
C9orf95! 219147_s_at! 1.56! 5.19E$08! 2.66E$06!
LOC100505989! 238103_at! 1.55! 1.28E$09! 2.64E$07!
CHMP4C! 226803_at! 1.53! 6.88E$09! 7.61E$07!
TXNRD3! 59631_at! 1.53! 4.21E$08! 2.31E$06!
CBLB! 227900_at! 1.50! 1.68E$09! 3.19E$07!
MAP7! 202890_at! 1.49! 4.41E$08! 2.38E$06!
SAMD5! 228653_at! 1.49! 7.42E$09! 7.94E$07!
MAL2! 224650_at! 1.48! 3.85E$08! 2.19E$06!
RELN! 205923_at! 1.47! 2.65E$08! 1.67E$06!
FAT3! 236029_at! 1.46! 6.49E$10! 1.97E$07!
PGAP1! 244321_at! 1.45! 1.38E$08! 1.15E$06!
ESRP2! 229223_at! 1.44! 2.03E$07! 6.61E$06!
PPM1H! 212686_at! 1.42! 3.95E$09! 5.48E$07!
FAM83H! 226129_at! 1.42! 2.44E$10! 1.14E$07!
LOC100506713! 229833_at! 1.42! 5.82E$09! 6.77E$07!
PCDH7! 205535_s_at! 1.40! 2.87E$09! 4.51E$07!
ST20! 217104_at! 1.40! 2.41E$07! 7.51E$06!
TMEM45A! 219410_at! 1.40! 4.33E$08! 2.35E$06!
PPP2R1B! 222351_at! 1.40! 2.16E$09! 3.79E$07!
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Figure S1: Gene expression analysis after HMGA1 silencing in MDA-MB-231 cells. Downregulation of 
selected genes after HMGA1 silencing (gray bar) was measured by qRTPCR. Expression was normalized to the 
level in MDA-MB-231 cells transfected with siCTRL; GAPDH was used as an internal control. Data are presented 
as the mean ± SD (n=3) (***p<0.001; **p<0.01; *p<0.05). 
 
Figure S2: Western blot showing GTSE1 protein levels in transformed and non-transformed cell lines. Non-
transformed cell lines are BM (Human bone marrow-derived multipotent adult stem cells), HH (Human heart-
derived multipotent adult stem cells), Wi38, and IMR-90. Transformed cell lines are MCF10A, MCF7, MDA-MB-
231, HCT116, and U2OS. 
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Karp-Rabin algorithm 
The classic approach to DNA motif discovery is to start by solving a local multiple 
alignment problem, using specific assumptions and statistical hypothesis. In a more 
general setting, after finding a set of similar—multiply aligned—substrings of the 
same length as the strings in the input, there is the necessity to compute a barycentric 
sequence: the “most representative string”, according to some criteria, for the found 
set. This problem is, in general, NP-hard, therefore some constraints must be 
introduced to cut the search space to a feasible size. In order to find a manageable 
solution, the consensus problem is then reduced to the fixed-layout consensus 
problem, thereby obtaining the sought computational cut on the search space.  
The general strategy used to tackle the problem is based on the introduction of a data 
structure encoding ‘à la Karp-Rabin’. The Karp-Rabin algorithm (Karp and Rabin 
1987) solves the pattern discovery problem on the exact string matching background. 
This algorithm (reasonably) assumes that it is possible to efficiently shift a vector of 
bits and efficiently perform arithmetical operations on integers as strings of bits. To 
take advantage of these assumptions, a string should be seen like an integer, mapping 
each character of the underlying alphabet Σ in a digit using a function fm. For 
example, in the DNA context, Σ = {A, C, G, T} can be mapped into Σ ‘ = {0, 1, 2, 3}. 
For a given text string T, let Tr denote the ℓ−length substring of T starting at character 
r. It is then possible to define the following function:  
! !! = ! !!!!!!!!! ∙ !! ! ! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 1  ! !! = ! ∙ ! !!!! − ! ! !!! ∙ !! ! ! − 1 + !! ! ! + ! − 1  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 2  
The following statement holds: there is an occurrence of a pattern P starting at 
position r of T if and only if H(P) = H(Tr).  
Karp and Rabin introduced a method called the randomized fingerprint method, 
which preserves the spirit of the above numerical approach, but allows dealing with 
larger numbers in an extremely efficient way. It is a randomized method because it 
introduces a probability of error, but the probability that a false match occurs can be 
bound as stated: the Karp-Rabin randomized algorithm for pattern matching requires ! ! +! !time and has a probability of error ! 1/! .  
The fingerprint function is especially useful when dealing with long patterns. It allows 
obtaining reasonably small and usable encoding numbers, to compare against each 
other. In this work, however, we use only the first part of the idea since we are 
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interested in finding short substrings, a reasonable hypothesis from a biological point 
of view. 
The problem can then be specified as follows: let ℱ = !!,… , !!  be the set of 
sequences (not necessarily of the same length), d the number of variations allowed in 
comparisons, and q a parameter denoting the minimum size of the set of ℱ-elements 
containing a closest substring (motif) of length ℓ with at most d variations. Without 
loss of generality, we consider input sequences of the same length n. 
ScanPro algorithm 
For a string s over Σ, we introduce the following notation: 
- !  denotes the length of ! 
- ! !  is the i-th character of the string ! 
- ! !… ! + !− 1  is the substring of ! characters starting from ! !  
- ! ⊴ ! denotes that ! is a substring of ! 
The Hamming distance dH between two strings of the same length is the number of 
symbols (nucleotides) that are different. 
The algorithm aims at solving the fixed-layout (ℓ, d, q)-consensus problem, and then 
extends the results to obtain an approximate solution for the (ℓ, d, q)-consensus 
problem solution. The difference with solving immediately the former problem lies in 
the generation step of the consensus sequence and in the final complexity. 
Furthermore, thanks to the fixed-layout approach, it becomes possible to propose 
versions of the algorithm that exploit new biological constraints on protein/DNA 3D 
binding (Sagot et al. 1995). 
We classify error layouts into two classes: basic and shifted. The algorithm exploits 
the relation between these classes to perform a cost-effective encoding of substrings 
according to all possible layouts. A generic error layout !! = !!,… , !! , such that 1 ≤ !! < !… !< !! ≤ ℓ, is the set of the d positions where an error may occur during a 
comparison between strings. Without loss of generality, we assume that i1 is strictly 
greater than 1, that is no error can be in the first position; in this way there are !"# = !!!!  error layouts called !" = !"!,… , !"!"# . Basic layouts, !"# , are 
characterized by having !! = ℓ and are !!!!!!  overall. Shifted layouts relative to a 
given basic layout !"#! are denoted by !"#!,! and look like !! − !,… , !! − ! , with !! − ! ≥ 2. 
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For a given error layout, the function !"_!"#$: !!×!" → ℕ  gives the encoding of a 
string of !− ! characters. For each string ! ∈ ℱ, with ! = !, and each basic layout !"#! = !!,… , !! , we have to encode all possible ! − !+ 1 substrings of length ! in 
s, thus perform !(! ∙ !) operations (for the base case). Considering a shifted layout !"#!,! = !! − !,… , !! − ! , with ! = 1,… , !! − 2 , we obtain the encoding of the 
substring ! !,… , ! + !− 1  for the given layout by taking the encoding of ! ! −1,… , ! + !− 2  for the error layout !"#!,!!!, performing a left shift and adding the 
value relative to ! ! + !− 1 , making !(!)  operations only. [In a left-to-right 
traveling of the string a right-to-left shift of the error-layout (in the string) takes 
places. Hence, a recursive computation with base case corresponding to the basic 
layouts can be -and in fact is- implemented, allowing for occurrences of substrings 
containing any possible error layout to be searched by ScanPro.] 
Since ! = 4, we map the alphabet on ℤ! using only 2 bits for each character. Hence, 
an !-characters-long string is mapped into a 2! bits integer number, so any shift 
involves only 2 bits. 
The implementation of the algorithm exploits this compact binary representation to 
improve performances. This idea was suggested by the Shift-Or algorithm (Baeza-
Yates and Gonnet 1992). 
The function !"_!"#$ returns a value used as index of an array: in each position c of 
this array there is a pointer to a matrix !! of dimension !"#× ! + 1 , with ! = ℱ , 
whose elements are lists of positions from column 1 to !, while column ! + 1 
contains the “rank”, that is the number of different strings ! ∈ ℱ in which we can find 
that specific motif. !! !, ! ≠ !"##  if in !!  there exists a substring !  such that ! = ! and !"_!"#$ !, !"! = !. A rank is incremented when an element is put in a 
empty position in the relative row. If this last value is greater than the quorum, the 
motif is a solution for the fixed-layout problem and we retrieve all positions of the 
occurrences using a generalized suffix tree. Using these occurrences we can then 
generate a consensus !!, according to a consensus string model (i.e. the majority 
string). Finally, thanks to the previous data structure, it is possible to have in constant 
time all the positions of the substrings !!, such that !! !! , !! ≤ !. 
 
 
